101
|
Gyanwali B, Lui B, Tan CS, Chong EJY, Vrooman H, Chen C, Hilal S. Cerebral Microbleeds and White Matter Hyperintensities are Associated with Cognitive Decline in an Asian Memory Clinic Study. Curr Alzheimer Res 2021; 18:399-413. [PMID: 34420506 DOI: 10.2174/1567205018666210820125543] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Revised: 05/21/2021] [Accepted: 05/29/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Cerebral Small Vessel Disease (SVD); lacunes, Cerebral Microbleeds (CMBs), and White Matter Hyperintensities (WMH) have a vital role in cognitive impairment and dementia. SVD in lobar location is related to cerebral amyloid angiopathy, whereas SVD in a deep location with hypertensive arteriopathy. It remains unclear how different locations of SVD affect long-term cognitive decline. The present study aimed to analyse the association between different locations and severity of SVD with global and domain-specific cognitive decline over the follow-up interval of 3 years. METHODS We studied 428 participants who had performed MRI scans at baseline and at least 3 neuropsychological assessments. Locations of lacunes and CMBs were categorized into strictly lobar, strictly deep and mixed-location, WMH volume into anterior and posterior. The National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Harmonization Neuropsychological Battery was used to assess cognitive function. To analyse the association between baseline location and severity of SVD with cognitive decline, linear regression models with generalized estimated equations were constructed to calculate the mean difference, 95% confidence interval and two-way interaction factor between time and SVD. RESULTS Increased numbers of baseline CMBs were associated with a decline in global cognition as well as a decline in executive function and memory domains. Location-specific analysis showed similar results with strictly lobar CMBs. There was no association with strictly deep and mixed-location CMBs with cognitive decline. Baseline WMH volume was associated with a decline in global cognition, executive function and memory. Similar results were obtained with anterior and posterior WMH volumes. Lacunes and their locations were not associated with cognitive decline. CONCLUSION Strictly lobar CMBs, as well as WMH volume in anterior and posterior regions, were associated with cognitive decline. Future research focuses are warranted to evaluate interventions that may prevent cognitive decline related to SVD.
Collapse
Affiliation(s)
- Bibek Gyanwali
- Memory Aging & Cognition Centre, National University Health System, 21 Lower Kent Ridge Rd, Singapore
| | - Benedict Lui
- Memory Aging & Cognition Centre, National University Health System, 21 Lower Kent Ridge Rd, Singapore
| | - Chuen S Tan
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 21 Lower Kent Ridge Rd, Singapore
| | - Eddie J Y Chong
- Department of Psychological Medicine, National University Hospital, 21 Lower Kent Ridge Rd, Singapore
| | - Henri Vrooman
- Departments of Radiology & Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Christopher Chen
- Memory Aging & Cognition Centre, National University Health System, 21 Lower Kent Ridge Rd, Singapore
| | - Saima Hilal
- Memory Aging & Cognition Centre, National University Health System, 21 Lower Kent Ridge Rd, Singapore
| |
Collapse
|
102
|
Rastogi A, Weissert R, Bhaskar SMM. Emerging role of white matter lesions in cerebrovascular disease. Eur J Neurosci 2021; 54:5531-5559. [PMID: 34233379 DOI: 10.1111/ejn.15379] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 06/26/2021] [Accepted: 06/26/2021] [Indexed: 12/12/2022]
Abstract
White matter lesions have been implicated in the setting of stroke, dementia, intracerebral haemorrhage, several other cerebrovascular conditions, migraine, various neuroimmunological diseases like multiple sclerosis, disorders of metabolism, mitochondrial diseases and others. While much is understood vis a vis neuroimmunological conditions, our knowledge of the pathophysiology of these lesions, and their role in, and implications to, management of cerebrovascular diseases or stroke, especially in the elderly, are limited. Several clinical assessment tools are available for delineating white matter lesions in clinical practice. However, their incorporation into clinical decision-making and specifically prognosis and management of patients is suboptimal for use in standards of care. This article sought to provide an overview of the current knowledge and recent advances on pathophysiology, as well as clinical and radiological assessment, of white matter lesions with a focus on its development, progression and clinical implications in cerebrovascular diseases. Key indications for clinical practice and recommendations on future areas of research are also discussed. Finally, a conceptual proposal on putative mechanisms underlying pathogenesis of white matter lesions in cerebrovascular disease has been presented. Understanding of pathophysiology of white matter lesions and how they mediate outcomes is important to develop therapeutic strategies.
Collapse
Affiliation(s)
- Aarushi Rastogi
- South Western Sydney Clinical School, University of New South Wales (UNSW), Liverpool, New South Wales, Australia.,Neurovascular Imaging Laboratory, Clinical Sciences Stream, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia
| | - Robert Weissert
- Department of Neurology, Regensburg University Hospital, University of Regensburg, Regensburg, Germany
| | - Sonu Menachem Maimonides Bhaskar
- South Western Sydney Clinical School, University of New South Wales (UNSW), Liverpool, New South Wales, Australia.,Neurovascular Imaging Laboratory, Clinical Sciences Stream, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.,NSW Brain Clot Bank, NSW Health Pathology, Sydney, New South Wales, Australia.,Department of Neurology and Neurophysiology, Liverpool Hospital and South Western Sydney Local Health District, Sydney, New South Wales, Australia
| |
Collapse
|
103
|
Xu M, Cheng Y, Zhang S, Zhang S, Song Q, Zheng L, Liu M, Liu M. Higher cerebral small vessel disease burden is associated with smaller hematoma volume in mixed-location intracerebral hemorrhage. Microcirculation 2021; 28:e12705. [PMID: 33977609 DOI: 10.1111/micc.12705] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 05/02/2021] [Indexed: 02/05/2023]
Abstract
OBJECTIVE To study the relationship between cerebral small vessel disease (CSVD) and hematoma volume in mixed-location intracerebral hemorrhage (ICH), and non-mixed ICH (hypertensive arteriopathy/cerebral amyloid angiopathy-related ICH). METHODS We consecutively collected patients with primary ICH with MRI. Mixed-location ICH was defined as having ICH or cerebral microbleeds (CMBs) in both lobar and deep regions. CSVD markers including lacunes, white matter hyperintensities (WMH), CMBs, and enlarged perivascular spaces (EPVS) were assessed on brain MRI during hospitalization. Multivariable binary logistic regression (≥30 ml vs. <30 ml) and linear regression analyses (log-transformed hematoma volume as dependent variable) were implemented to explore the association between CSVD and hematoma volume. RESULTS Of the 167 included patients, 69 (41.3%) had mixed-location ICH, with higher prevalence of lacune, more CMB count, higher WMH score and total CSVD score than those with non-mixed ICH (all p < .001). Higher WMH score was associated with lower risk of hematoma volume ≥30 ml (adjusted OR 0.521, 95% CI 0.299-0.908, p = .021) in patients with mixed-location ICH. Also, multivariable linear regression showed the association of smaller hematoma volume with higher CSVD burden, especially in mixed-location ICH (β = -0.349, p = .019 for CMB ≥ 5; β = -0.183, p < .001 for WMH score; β = -0.456, p = .002 for EPVS>20 in basal ganglia and/or centrum semiovale; β = -0.256, p = .002 for CSVD score), while these relationships were not observed in non-mixed ICH. CONCLUSIONS Higher CSVD burden is associated with smaller hematoma volume in mixed-location ICH, but not in non-mixed ICH, which is novel and needs further studies with larger sample size to confirm our results and explore the underlying mechanisms.
Collapse
Affiliation(s)
- Mangmang Xu
- Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
| | - Yajun Cheng
- Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
| | - Shihong Zhang
- Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
| | - Shuting Zhang
- Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
| | - Quhong Song
- Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
| | - Lukai Zheng
- Institute for Stroke and Dementia Research, Ludwig Maximilian University Hospital of Munich (KUM), Munich, Germany
| | - Meng Liu
- Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
| | - Ming Liu
- Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
104
|
Mutimer CA, Keragala CB, Markus HS, Werring DJ, Cloud GC, Medcalf RL. Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target? Stroke 2021; 52:2707-2714. [PMID: 34126761 DOI: 10.1161/strokeaha.120.033107] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cerebral amyloid angiopathy is a devastating cause of intracerebral hemorrhage for which there is no specific secondary stroke prevention treatment. Here we review the current literature regarding cerebral amyloid angiopathy pathophysiology and treatment, as well as what is known of the fibrinolytic pathway and its interaction with amyloid. We postulate that tranexamic acid is a potential secondary stroke prevention treatment agent in sporadic cerebral amyloid angiopathy, although further research is required.
Collapse
Affiliation(s)
- Chloe A Mutimer
- Department of Neurology, Alfred Hospital, Melbourne, Australia (C.A.M., G.C.C.)
| | - Charithani B Keragala
- Australian Centre for Blood Diseases (C.B.K., R.L.M.), Monash University, Melbourne, Australia
| | - Hugh S Markus
- Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge, United Kingdom (H.S.M.)
| | - David J Werring
- Stroke Research Centre, Queen Square Institute of Neurology, London, United Kingdom (D.J.W.)
| | - Geoffrey C Cloud
- Department of Neurology, Alfred Hospital, Melbourne, Australia (C.A.M., G.C.C.).,Department of Clinical Neuroscience, Central Clinical School (G.C.C.), Monash University, Melbourne, Australia
| | - Robert L Medcalf
- Australian Centre for Blood Diseases (C.B.K., R.L.M.), Monash University, Melbourne, Australia
| |
Collapse
|
105
|
Medrano-Martorell S, Capellades J, Jiménez-Conde J, González-Ortiz S, Vilas-González M, Rodríguez-Campello A, Ois Á, Cuadrado-Godia E, Avellaneda C, Fernández I, Merino-Peña E, Roquer J, Martí-Fàbregas J, Giralt-Steinhauer E. Risk factors analysis according to regional distribution of white matter hyperintensities in a stroke cohort. Eur Radiol 2021; 32:272-280. [PMID: 34117555 DOI: 10.1007/s00330-021-08106-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 05/18/2021] [Accepted: 05/27/2021] [Indexed: 01/11/2023]
Abstract
OBJECTIVES The spectrum of distribution of white matter hyperintensities (WMH) may reflect different functional, histopathological, and etiological features. We examined the relationships between cerebrovascular risk factors (CVRF) and different patterns of WMH in MRI using a qualitative visual scale in ischemic stroke (IS) patients. METHODS We assembled clinical data and imaging findings from patients of two independent cohorts with recent IS. MRI scans were evaluated using a modified visual scale from Fazekas, Wahlund, and Van Swieten. WMH distributions were analyzed separately in periventricular (PV-WMH) and deep (D-WMH) white matter, basal ganglia (BG-WMH), and brainstem (B-WMH). Presence of confluence of PV-WMH and D-WMH and anterior-versus-posterior WMH predominance were also evaluated. Statistical analysis was performed with SPSS software. RESULTS We included 618 patients, with a mean age of 72 years (standard deviation [SD] 11 years). The most frequent WMH pattern was D-WMH (73%). In a multivariable analysis, hypertension was associated with PV-WMH (odds ratio [OR] 1.79, 95% confidence interval [CI] 1.29-2.50, p = 0.001) and BG-WMH (OR 2.13, 95% CI 1.19-3.83, p = 0.012). Diabetes mellitus was significantly related to PV-WMH (OR 1.69, 95% CI 1.24-2.30, p = 0.001), D-WMH (OR 1.46, 95% CI 1.07-1.49, p = 0.017), and confluence patterns of D-WMH and PV-WMH (OR 1.62, 95% CI 1.07-2.47, p = 0.024). Hyperlipidemia was found to be independently related to brainstem distribution (OR 1.70, 95% CI 1.08-2.69, p = 0.022). CONCLUSIONS Different CVRF profiles were significantly related to specific WMH spatial distribution patterns in a large IS cohort. KEY POINTS • An observational study of WMH in a large IS cohort was assessed by a modified visual evaluation. • Different CVRF profiles were significantly related to specific WMH spatial distribution patterns. • Distinct WMH anatomical patterns could be related to different pathophysiological mechanisms.
Collapse
Affiliation(s)
- Santiago Medrano-Martorell
- Department of Neuroradiology, Hospital Clínic i Provincial, Villarroel, 170, Barcelona, Spain.
- Department of Neuroradiology, Hospital del Mar, Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
| | - Jaume Capellades
- Department of Neuroradiology, Hospital del Mar, Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Jordi Jiménez-Conde
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Sofía González-Ortiz
- Department of Neuroradiology, Hospital Clínic i Provincial, Villarroel, 170, Barcelona, Spain
- Department of Neuroradiology, Hospital del Mar, Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Marta Vilas-González
- Department of Neuroradiology, Hospital del Mar, Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Ana Rodríguez-Campello
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Ángel Ois
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Elisa Cuadrado-Godia
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Carla Avellaneda
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Isabel Fernández
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Elisa Merino-Peña
- Department of Neuroradiology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Jaume Roquer
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Joan Martí-Fàbregas
- Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Eva Giralt-Steinhauer
- Department of Neurology, Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona (UAB)/DCEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
| |
Collapse
|
106
|
Kozberg MG, Perosa V, Gurol ME, van Veluw SJ. A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke 2021; 16:356-369. [PMID: 33252026 PMCID: PMC9097498 DOI: 10.1177/1747493020974464] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Cerebral amyloid angiopathy is a common small vessel disease in the elderly involving vascular amyloid-β deposition. Cerebral amyloid angiopathy is one of the leading causes of intracerebral hemorrhage and a significant contributor to age-related cognitive decline. The awareness of a diagnosis of cerebral amyloid angiopathy is important in clinical practice as it impacts decisions to use lifelong anticoagulation or nonpharmacological alternatives to anticoagulation such as left atrial appendage closure in patients who have concurrent atrial fibrillation, another common condition in older adults. This review summarizes the latest literature regarding the management of patients with sporadic cerebral amyloid angiopathy, including diagnostic criteria, imaging biomarkers for cerebral amyloid angiopathy severity, and management strategies to decrease intracerebral hemorrhage risk. In a minority of patients, the presence of cerebral amyloid angiopathy triggers an autoimmune inflammatory reaction, referred to as cerebral amyloid angiopathy-related inflammation, which is often responsive to immunosuppressive treatment in the acute phase. Diagnosis and management of cerebral amyloid angiopathy-related inflammation will be presented separately. While there are currently no effective therapeutics available to cure or halt the progression of cerebral amyloid angiopathy, we discuss emerging avenues for potential future interventions.
Collapse
Affiliation(s)
- Mariel G Kozberg
- MassGeneral Institute for Neurodegenerative Disease, 2348Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
- Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA,USA
| | - Valentina Perosa
- MassGeneral Institute for Neurodegenerative Disease, 2348Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
- Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA,USA
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany
| | - M Edip Gurol
- Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA,USA
| | - Susanne J van Veluw
- MassGeneral Institute for Neurodegenerative Disease, 2348Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
- Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology, 2348Massachusetts General Hospital, Harvard Medical School, Boston, MA,USA
| |
Collapse
|
107
|
Inoue Y, Ando Y, Misumi Y, Ueda M. Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy. Int J Mol Sci 2021; 22:ijms22083869. [PMID: 33918041 PMCID: PMC8068954 DOI: 10.3390/ijms22083869] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/01/2021] [Accepted: 04/01/2021] [Indexed: 12/18/2022] Open
Abstract
Cerebral amyloid angiopathy (CAA) is characterized by accumulation of amyloid β (Aβ) in walls of leptomeningeal vessels and cortical capillaries in the brain. The loss of integrity of these vessels caused by cerebrovascular Aβ deposits results in fragile vessels and lobar intracerebral hemorrhages. CAA also manifests with progressive cognitive impairment or transient focal neurological symptoms. Although development of therapeutics for CAA is urgently needed, the pathogenesis of CAA remains to be fully elucidated. In this review, we summarize the epidemiology, pathology, clinical and radiological features, and perspectives for future research directions in CAA therapeutics. Recent advances in mass spectrometric methodology combined with vascular isolation techniques have aided understanding of the cerebrovascular proteome. In this paper, we describe several potential key CAA-associated molecules that have been identified by proteomic analyses (apolipoprotein E, clusterin, SRPX1 (sushi repeat-containing protein X-linked 1), TIMP3 (tissue inhibitor of metalloproteinases 3), and HTRA1 (HtrA serine peptidase 1)), and their pivotal roles in Aβ cytotoxicity, Aβ fibril formation, and vessel wall remodeling. Understanding the interactions between cerebrovascular Aβ deposits and molecules that accumulate with Aβ may lead to discovery of effective CAA therapeutics and to the identification of biomarkers for early diagnosis.
Collapse
Affiliation(s)
- Yasuteru Inoue
- Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan; (Y.M.); (M.U.)
- Correspondence: ; Tel.: +81-96-373-5893; Fax: +81-96-373-5895
| | - Yukio Ando
- Department of Amyloidosis Research, Nagasaki International University, Sasebo 859-3298, Japan;
| | - Yohei Misumi
- Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan; (Y.M.); (M.U.)
| | - Mitsuharu Ueda
- Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan; (Y.M.); (M.U.)
| |
Collapse
|
108
|
Zanon Zotin MC, Sveikata L, Viswanathan A, Yilmaz P. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr Opin Neurol 2021; 34:246-257. [PMID: 33630769 PMCID: PMC7984766 DOI: 10.1097/wco.0000000000000913] [Citation(s) in RCA: 104] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
PURPOSE OF REVIEW We present recent developments in the field of small vessel disease (SVD)-related vascular cognitive impairment, including pathological mechanisms, updated diagnostic criteria, cognitive profile, neuroimaging markers and risk factors. We further address available management and therapeutic strategies. RECENT FINDINGS Vascular and neurodegenerative pathologies often co-occur and share similar risk factors. The updated consensus criteria aim to standardize vascular cognitive impairment (VCI) diagnosis, relying strongly on cognitive profile and MRI findings. Aggressive blood pressure control and multidomain lifestyle interventions are associated with decreased risk of cognitive impairment, but disease-modifying treatments are still lacking. Recent research has led to a better understanding of mechanisms leading to SVD-related cognitive decline, such as blood-brain barrier dysfunction, reduced cerebrovascular reactivity and impaired perivascular clearance. SUMMARY SVD is the leading cause of VCI and is associated with substantial morbidity. Tackling cardiovascular risk factors is currently the most effective approach to prevent cognitive decline in the elderly. Advanced imaging techniques provide tools for early diagnosis and may play an important role as surrogate markers for cognitive endpoints in clinical trials. Designing and testing disease-modifying interventions for VCI remains a key priority in healthcare.
Collapse
Affiliation(s)
- Maria Clara Zanon Zotin
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
- Center for Imaging Sciences and Medical Physics. Department of Medical Imaging, Hematology and Clinical Oncology. Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - Lukas Sveikata
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
- Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Institute of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Anand Viswanathan
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
| | - Pinar Yilmaz
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
- Departments of Epidemiology and Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
| |
Collapse
|
109
|
Chwalisz BK. Cerebral amyloid angiopathy and related inflammatory disorders. J Neurol Sci 2021; 424:117425. [PMID: 33840507 DOI: 10.1016/j.jns.2021.117425] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 10/27/2020] [Accepted: 03/24/2021] [Indexed: 11/19/2022]
Abstract
Inflammatory cerebral amyloid angiopathy is a largely reversible inflammatory vasculopathy that develops in an acute or subacute fashion in reaction to amyloid protein deposition in the central nervous system blood vessels. There are two recognized pathologically characterized variants: cerebral amyloid angiopathy-related inflammation (CAAri) and A beta-related angiitis (ABRA). Both variants produce a clinical picture that resembles primary angiitis of the CNS but is distinguished by a characteristic radiologic appearance. Although originally defined as a clinicopathologic diagnosis, it can now often be diagnosed based on clinicoradiologic criteria, though confirmation with brain and meningeal biopsy is still required in some cases. This disorder typically responds to steroids but addition of other immune suppressants may be needed in some cases to control the disease.
Collapse
Affiliation(s)
- B K Chwalisz
- Department of Neurology, Massachusetts General Hospital/Harvard Medical School, 15 Parkman Street, Suite 835, Boston, MA 02114, USA; Division of Neuro-Ophthalmology, Department of Ophthalmology, Massachusetts Eye & Ear Infirmary/Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
110
|
Gokcal E, Horn MJ, van Veluw SJ, Frau-Pascual A, Das AS, Pasi M, Fotiadis P, Warren AD, Schwab K, Rosand J, Viswanathan A, Polimeni JR, Greenberg SM, Gurol ME. Lacunes, Microinfarcts, and Vascular Dysfunction in Cerebral Amyloid Angiopathy. Neurology 2021; 96:e1646-e1654. [PMID: 33536272 PMCID: PMC8032369 DOI: 10.1212/wnl.0000000000011631] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 12/18/2020] [Indexed: 01/29/2023] Open
Abstract
OBJECTIVE To analyze the relationship of lacunes with cortical cerebral microinfarcts (CMIs), to assess their association with vascular dysfunction, and to evaluate their effect on the risk of incident intracerebral hemorrhage (ICH) in cerebral amyloid angiopathy (CAA). METHODS The count and topography of lacunes (deep/lobar), CMIs, and white matter hyperintensity (WMH) volume were retrospectively analyzed in a prospectively enrolled CAA cohort that underwent high-resolution research MRIs. The relationship of lacunes with CMIs and other CAA-related markers including time to peak (TTP) of blood oxygen level-dependent signal, an established measure of vascular dysfunction, was evaluated in multivariate models. Adjusted Cox regression models were used to investigate the relationship between lacunes and incident ICH. RESULTS The cohort consisted of 122 patients with probable CAA without dementia (mean age, 69.4 ± 7.6 years). Lacunes were present in 31 patients (25.4%); all but one were located in lobar regions. Cortical CMIs were more common in patients with lacunes compared to patients without lacunes (51.6% vs 20.9%, p = 0.002). TTP was not associated with either lacunes or CMIs (both p > 0.2) but longer TTP response independently correlated with higher WMH volume (p = 0.001). Lacunes were associated with increased ICH risk in univariate and multivariate Cox regression models (p = 0.048 and p = 0.026, respectively). CONCLUSIONS Our findings show a high prevalence of lobar lacunes, frequently coexisting with CMIs in CAA, suggesting that these 2 lesion types may be part of a common spectrum of CAA-related infarcts. Lacunes were not related to vascular dysfunction but predicted incident ICH, favoring severe focal vessel involvement rather than global ischemia as their mechanism.
Collapse
Affiliation(s)
- Elif Gokcal
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Mitchell J Horn
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Susanne J van Veluw
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Aina Frau-Pascual
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Alvin S Das
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Marco Pasi
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Panagiotis Fotiadis
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Andrew D Warren
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Kristin Schwab
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Jonathan Rosand
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Anand Viswanathan
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Jonathan R Polimeni
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - Steven M Greenberg
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France
| | - M Edip Gurol
- From the J. Philip Kistler Hemorrhagic Stroke Research Program, Department of Neurology (E.G., M.J.H., S.J.v.V., M.P., P.F., A.D.W., K.S., J.R., A.V., S.M.G., M.E.G.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.F.-P., J.R.P.), Charlestown; Department of Neurology (A.S.D.), Massachusetts General Hospital, Boston; and Department of Neurology, Stroke Unit (M.P.), Univ-Lille, Inserm U1171, CHU Lille, France.
| |
Collapse
|
111
|
Raposo N, Zanon Zotin MC, Schoemaker D, Xiong L, Fotiadis P, Charidimou A, Pasi M, Boulouis G, Schwab K, Schirmer MD, Etherton MR, Gurol ME, Greenberg SM, Duering M, Viswanathan A. Peak Width of Skeletonized Mean Diffusivity as Neuroimaging Biomarker in Cerebral Amyloid Angiopathy. AJNR Am J Neuroradiol 2021; 42:875-881. [PMID: 33664113 DOI: 10.3174/ajnr.a7042] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 11/20/2020] [Indexed: 12/19/2022]
Abstract
BACKGROUND AND PURPOSE Whole-brain network connectivity has been shown to be a useful biomarker of cerebral amyloid angiopathy and related cognitive impairment. We evaluated an automated DTI-based method, peak width of skeletonized mean diffusivity, in cerebral amyloid angiopathy, together with its association with conventional MRI markers and cognitive functions. MATERIALS AND METHODS We included 24 subjects (mean age, 74.7 [SD, 6.0] years) with probable cerebral amyloid angiopathy and mild cognitive impairment and 62 patients with MCI not attributable to cerebral amyloid angiopathy (non-cerebral amyloid angiopathy-mild cognitive impairment). We compared peak width of skeletonized mean diffusivity between subjects with cerebral amyloid angiopathy-mild cognitive impairment and non-cerebral amyloid angiopathy-mild cognitive impairment and explored its associations with cognitive functions and conventional markers of cerebral small-vessel disease, using linear regression models. RESULTS Subjects with Cerebral amyloid angiopathy-mild cognitive impairment showed increased peak width of skeletonized mean diffusivity in comparison to those with non-cerebral amyloid angiopathy-mild cognitive impairment (P < .001). Peak width of skeletonized mean diffusivity values were correlated with the volume of white matter hyperintensities in both groups. Higher peak width of skeletonized mean diffusivity was associated with worse performance in processing speed among patients with cerebral amyloid angiopathy, after adjusting for other MRI markers of cerebral small vessel disease. The peak width of skeletonized mean diffusivity did not correlate with cognitive functions among those with non-cerebral amyloid angiopathy-mild cognitive impairment. CONCLUSIONS Peak width of skeletonized mean diffusivity is altered in cerebral amyloid angiopathy and is associated with performance in processing speed. This DTI-based method may reflect the degree of white matter structural disruption in cerebral amyloid angiopathy and could be a useful biomarker for cognition in this population.
Collapse
Affiliation(s)
- N Raposo
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts .,Department of Neurology (N.R.), Centre Hospitalier Universitaire de Toulouse, Toulouse, France.,Toulouse NeuroImaging Center (N.R.), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale, Toulouse, UPS, France
| | - M C Zanon Zotin
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.,Center for Imaging Sciences and Medical Physics (M.C.Z.Z.). Department of Medical Imaging, Hematology and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil;, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil
| | - D Schoemaker
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - L Xiong
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - P Fotiadis
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - A Charidimou
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - M Pasi
- Department of Neurology (M.P.), Centre Hospitalier Universitaire de Lille, Lille, France
| | - G Boulouis
- Department of Neuroradiology (G.B.), Centre Hospitalier Sainte-Anne, Université Paris-Descartes, Paris, France
| | - K Schwab
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - M D Schirmer
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.,Computer Science and Artificial Intelligence Lab (M.D.S.), Massachusetts Institute of Technology, Boston, Massachusetts.,Department of Population Health Sciences (M.D.S.), German Center for Neurodegenerative Diseases, Bonn, Germany
| | - M R Etherton
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - M E Gurol
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - S M Greenberg
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - M Duering
- Medical Image Analysis Center and Quantitative Biomedical Imaging Group (M.D.), Department of Biomedical Engineering, University of Basel, Basel, Switzerland
| | - A Viswanathan
- From the Stroke Research Center (N.R., M.C.Z.Z., D.S., L.X., P.F., A.C., K.S., M.D.S., M.R.E., M.E.G., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
112
|
Zhang SC, Jia JJ, Zhao HL, Zhou B, Wang W, Lu XH, Wang H, Wang ZF, Wu WP. Early MRI imaging and follow-up study in cerebral amyloid angiopathy. Open Med (Wars) 2021; 16:257-263. [PMID: 33623821 PMCID: PMC7885301 DOI: 10.1515/med-2021-0212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Revised: 11/30/2020] [Accepted: 01/04/2021] [Indexed: 11/27/2022] Open
Abstract
Aim To study the imaging features of leukoaraiosis (LA) and hemorrhage in cerebral amyloid angiopathy (CAA) patients. Methods The earliest MRI images of probable CAA patients and non-CAA patients were collected. The characteristics of LA in the two groups were analyzed. Cerebral micro bleeding (CMB), superficial siderosis (SS), and intracranial hemorrhage (ICH) were recorded in the follow-up study. The space relationship between CMB or SS and ICH was assessed. Results We found that 10/21 (47.6%) patients had occipital prominent LA and 14/21 (66.7%) patients had subcortical punctate LA before the ICH, which was higher than that of the ones in the control group (p = 0.015 and 0.038, respectively). The recurrence rate of ICH was 100% (3/3) in patients with diffuse SS and 36.4% (4/11) in patients without. The recurrence rate of ICH was 60% (3/5) in patients with multiple-lobe CMBs and 44.4% (4/9) in those without. The location of the ICH and CMB was inconsistent. ICH occurred in the ipsilateral cerebral hemisphere of SS in three patients with diffuse SS. Conclusion LA, diffuse SS, and multiple-lobe CMBs are important imaging characteristics of CAA, which may help make early diagnosis and predict the recurrence of ICH.
Collapse
Affiliation(s)
- Shan-Chun Zhang
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Jian-Jun Jia
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Heng-Li Zhao
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Bo Zhou
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Wei Wang
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Xiang-Hui Lu
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Hao Wang
- Geriatric Cardiological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Zhen-Fu Wang
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| | - Wei-Ping Wu
- Geriatric Neurological Department of the Second Medical Centre and National Clinical Research Center of Geriatric Disease, Chinese People's Liberation Army General Hospital, Beijing, 100853, China
| |
Collapse
|
113
|
Xu M, Li B, Zhong D, Cheng Y, Wu Q, Zhang S, Zhang S, Wu B, Liu M. Cerebral Small Vessel Disease Load Predicts Functional Outcome and Stroke Recurrence After Intracerebral Hemorrhage: A Median Follow-Up of 5 Years. Front Aging Neurosci 2021; 13:628271. [PMID: 33679377 PMCID: PMC7933464 DOI: 10.3389/fnagi.2021.628271] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 01/26/2021] [Indexed: 02/05/2023] Open
Abstract
Background: Uncertainty exists over the long-term prognostic significance of cerebral small vessel disease (CSVD) in primary intracerebral hemorrhage (ICH). Methods: We performed a longitudinal analysis of CSVD and clinical outcomes in consecutive patients with primary ICH who had MRI. Baseline CSVD load (including white matter hyperintensities [WMH], cerebral microbleeds [CMBs], lacunes, and enlarged perivascular spaces [EPVS]) was evaluated. The cumulative CSVD score was calculated by combining the presence of each CSVD marker (range 0–4). We followed participants for poor functional outcome [modified Rankin scale [mRS] ≥ 4], stroke recurrence, and time-varying survival during a median follow-up of 4.9 [interquartile range [IQR] 3.1–6.0] years. Parsimonious and fuller multivariable logistic regression analysis and Cox-regression analysis were performed to estimate the association of CSVD markers, individually and collectively, with each outcome. Results: A total of 153 patients were included in the analyses. CMBs ≥ 10 [adjusted OR [adOR] 3.252, 95% CI 1.181–8.956, p = 0.023] and periventricular WMH (PWMH) (adOR 2.053, 95% CI 1.220–3.456, p = 0.007) were significantly associated with poor functional outcome. PWMH (adOR 2.908, 95% CI 1.230–6.878, p = 0.015) and lobar CMB severity (adOR 1.811, 95% CI 1.039–3.157, p = 0.036) were associated with stroke recurrence. The cumulative CSVD score was associated with poor functional outcome (adOR 1.460, 95% CI 1.017–2.096) and stroke recurrence (adOR 2.258, 95% CI 1.080–4.723). Death occurred in 36.1% (13/36) of patients with CMBs ≥ 10 compared with 18.8% (22/117) in those with CMB < 10 (adjusted HR 2.669, 95% CI 1.248–5.707, p = 0.011). In addition, the cumulative CSVD score ≥ 2 was associated with a decreased survival rate (adjusted HR 3.140, 95% CI 1.066–9.250, p = 0.038). Conclusions: Severe PWMH, CMB, or cumulative CSVD burden exert important influences on the long-term outcome of ICH.
Collapse
Affiliation(s)
- Mangmang Xu
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Baojin Li
- Department of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Di Zhong
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Yajun Cheng
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Qian Wu
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Shuting Zhang
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Shihong Zhang
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Bo Wu
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Ming Liu
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
114
|
Gokcal E, Horn MJ, Gurol ME. The role of biomarkers and neuroimaging in ischemic/hemorrhagic risk assessment for cardiovascular/cerebrovascular disease prevention. HANDBOOK OF CLINICAL NEUROLOGY 2021; 177:345-357. [PMID: 33632452 DOI: 10.1016/b978-0-12-819814-8.00021-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Stroke prevention in patients with atrial fibrillation is arguably one of the fastest developing areas in preventive medicine. The increasing use of direct oral anticoagulants and nonpharmacologic methods such as left atrial appendage closure for stroke prevention in these patients has increased clinicians' options for optimal care. Platelet antiaggregants are also commonly used in other ischemic cardiovascular and or cerebrovascular conditions. Long term use of oral anticoagulants for atrial fibrillation is associated with elevated risks of major bleeds including especially brain hemorrhages, which are known to have extremely poor outcomes. Neuroimaging and other biomarkers have been validated to stratify brain hemorrhage risk among older adults. A thorough understanding of these biomarkers is essential for selection of appropriate anticoagulant or left atrial appendage closure for stroke prevention in patients with atrial fibrillation. This article will address advances in the stratification of ischemic and hemorrhagic stroke risk among patients with atrial fibrillation and other conditions.
Collapse
Affiliation(s)
- Elif Gokcal
- Department of Neurology, Massachusetts General Hospital, Boston, MA, United States
| | - Mitchell J Horn
- Department of Neurology, Massachusetts General Hospital, Boston, MA, United States
| | - M Edip Gurol
- Department of Neurology, Massachusetts General Hospital, Boston, MA, United States.
| |
Collapse
|
115
|
Scheumann V, Schreiber F, Perosa V, Assmann A, Mawrin C, Garz C, Heinze HJ, Görtler M, Düzel E, Vielhaber S, Charidimou A, Schreiber S. MRI phenotyping of underlying cerebral small vessel disease in mixed hemorrhage patients. J Neurol Sci 2020; 419:117173. [PMID: 33068905 DOI: 10.1016/j.jns.2020.117173] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 10/03/2020] [Accepted: 10/06/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To investigate underlying cerebral small vessel disease (CSVD) in patients with mixed cerebral hemorrhages patterns and phenotype them according to the contribution of the two most common sporadic CSVD subtypes: cerebral amyloid angiopathy (CAA) vs. hypertensive arteriopathy (HA). METHODS Brain MRIs of patients with intracerebral hemorrhages (ICHs) and/or cerebral microbleeds (CMBs) were assessed for the full spectrum of CSVD markers using validated scales: ICHs, CMBs, cortical superficial siderosis (cSS), white matter hyperintensities, MRI-visible perivascular spaces (PVS). PVS predominance pattern was grouped as centrum-semiovale (CSO)-PVS predominance, basal-ganglia (BG)-PVS predominance, CSO-PVS and BG-PVS equality. Patients with mixed cerebral hemorrhages were classified into mixed CAA-pattern or mixed HA-pattern according to the existence of cSS and/or a CSO-PVS predominance pattern and comparisons were performed. RESULTS We included 110 patients with CAA (strictly lobar ICHs/CMBs), 33 with HA (strictly deep ICHs/CMBs) and 97 with mixed lobar/deep ICHs/CMBs. Mixed patients were more similar to HA with respect to their MRI-CSVD markers, vascular risk profile and cerebrospinal fluid (CSF) measures. In the mixed patients, 33 (34%) had cSS, a CSO-PVS predominance pattern, or both, and were defined as mixed CAA-pattern cases. The mixed CAA-pattern patients were more alike CAA patients regarding their MRI-CSVD markers, CSF and genetic profile. CONCLUSION Our findings suggest that the heterogeneous group of patients with mixed cerebral hemorrhages distribution can be further phenotyped according to the predominant underlying CSVD. cSS presence and a CSO-PVS predominance pattern could serve as strongly suggestive markers of a contribution from CAA among patients with mixed hemorrhages.
Collapse
Affiliation(s)
- Vincent Scheumann
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany.
| | - Frank Schreiber
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120 Magdeburg, Germany.
| | - Valentina Perosa
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120 Magdeburg, Germany; J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, 175 Cambridge Street, Boston, MA 02114, USA.
| | - Anne Assmann
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany.
| | - Christian Mawrin
- Institute of Neuropathology, Otto-von-Guericke-University Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Universitätsplatz 2, 39106 Magdeburg, Germany.
| | - Cornelia Garz
- German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120 Magdeburg, Germany; Leibniz Institute for Neurobiology (LIN), Brenneckestraße, 39118 Magdeburg, Germany.
| | - Hans-Jochen Heinze
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120 Magdeburg, Germany; Leibniz Institute for Neurobiology (LIN), Brenneckestraße, 39118 Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Universitätsplatz 2, 39106 Magdeburg, Germany.
| | - Michael Görtler
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany.
| | - Emrah Düzel
- German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120 Magdeburg, Germany; Leibniz Institute for Neurobiology (LIN), Brenneckestraße, 39118 Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Universitätsplatz 2, 39106 Magdeburg, Germany; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke-University Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany.
| | - Stefan Vielhaber
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120 Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Universitätsplatz 2, 39106 Magdeburg, Germany.
| | - Andreas Charidimou
- Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
| | - Stefanie Schreiber
- Department of Neurology, Otto-von-Guericke University, Leipziger Straße 44, 39120 Magdeburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120 Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Universitätsplatz 2, 39106 Magdeburg, Germany.
| |
Collapse
|
116
|
Regenhardt RW, Thon JM, Das AS, Thon OR, Charidimou A, Viswanathan A, Gurol ME, Chwalisz BK, Frosch MP, Cho TA, Greenberg SM. Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy-Related Inflammation. JAMA Neurol 2020; 77:1261-1269. [PMID: 32568365 PMCID: PMC7309570 DOI: 10.1001/jamaneurol.2020.1782] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Accepted: 03/20/2020] [Indexed: 07/27/2023]
Abstract
IMPORTANCE Cerebral amyloid angiopathy-related inflammation (CAA-ri), a distinct subtype of cerebral amyloid angiopathy, is characterized by an autoimmune reaction to cerebrovascular β-amyloid deposits. Outcomes and response to immunosuppressive therapy for CAA-ri are poorly understood. OBJECTIVE To identify clinical, neuroimaging, laboratory, pathologic, or treatment-related associations with outcomes after an episode of CAA-ri. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of prospectively identified individuals who presented from July 3, 1998, to November 27, 2017, with a median follow-up of 2.7 years (interquartile range, 1.0-5.5 years). The study included 48 consecutive patients with CAA-ri meeting diagnostic criteria who had at least 1 disease episode and subsequent outcome data. No patients refused or were excluded. EXPOSURES Prespecified candidate variables were immunosuppressive therapies, cerebrospinal fluid pleocytosis, magnetic resonance imaging findings of recent infarcts or contrast enhancement, and histopathologic evidence of vessel wall inflammation. MAIN OUTCOMES AND MEASURES Clinical improvement and worsening were defined by persistent changes in signs or symptoms, radiographic improvement by decreased subcortical foci of T2 hyperintensity or T1 enhancement, and radiographic worsening by increased subcortical T2 hyperintensity, T1 enhancement, or infarcts. Disease recurrence was defined as new-onset clinical symptoms associated with new imaging findings. RESULTS The 48 individuals in the study included 29 women and had a mean (SD) age of 68.9 (9.9) years. Results of presenting magnetic resonance imaging revealed that 10 of 29 patients with CAA-ri (34%) had T1 contrast enhancement, 30 of 32 (94%) had subcortical T2 hyperintensity (22 of 30 [73%] asymmetric), 7 of 32 (22%) had acute or subacute punctate infarcts, and 27 of 31 (87%) had microbleeds. Immunosuppressive treatments after first episodes included corticosteroids (33 [69%]), cyclophosphamide (6 [13%]), and mycophenolate (2 [4%]); 14 patients (29%) received no treatment. Clinical improvement and radiographic improvement were each more likely in individuals treated with an immunosuppressive agent than with no treatment (clinical improvement: 32 of 34 [94%] vs 7 of 14 [50%]; odds ratio, 16.0; 95% CI, 2.72-94.1; radiographic improvement: 24 of 28 [86%] vs 4 of 14 [29%]; odds ratio, 15.0; 95% CI, 3.12-72.1). Recurrence was less likely if CAA-ri was treated with any immunosuppressant agent than not (9 of 34 [26%] vs 10 of 14 [71%]; hazard ratio, 0.19; 95% CI, 0.07-0.48). When controlling for treatment, no variables were associated with outcomes aside from an association between APOE ɛ4 and radiographic improvement (odds ratio, 4.49; 95% CI, 1.11-18.2). CONCLUSIONS AND RELEVANCE These results from a relatively large series of patients with CAA-ri support the effectiveness of immunosuppressive treatment and suggest that early treatment may both improve the initial disease course and reduce the likelihood of recurrence. These results raise the possibility that early blunting of CAA-ri and the autoimmune response may have long-term benefits for the subsequent disease course.
Collapse
Affiliation(s)
- Robert W. Regenhardt
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Jesse M. Thon
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Alvin S. Das
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Olga R. Thon
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Andreas Charidimou
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Anand Viswanathan
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - M. Edip Gurol
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Bart K. Chwalisz
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Matthew P. Frosch
- Neuropathology Service, C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Tracey A. Cho
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City
| | - Steven M. Greenberg
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
| |
Collapse
|
117
|
Low A, Mak E, Malpetti M, Passamonti L, Nicastro N, Stefaniak JD, Savulich G, Chouliaras L, Su L, Rowe JB, Markus HS, O'Brien JT. In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2020; 92:jnnp-2020-323894. [PMID: 32917821 PMCID: PMC7803899 DOI: 10.1136/jnnp-2020-323894] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 07/06/2020] [Accepted: 08/05/2020] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Associations between cerebral small vessel disease (SVD) and inflammation have been largely examined using peripheral blood markers of inflammation, with few studies measuring inflammation within the brain. We investigated the cross-sectional relationship between SVD and in vivo neuroinflammation using [11C]PK11195 positron emission tomography (PET) imaging. METHODS Forty-two participants were recruited (according to NIA-AA guidelines, 14 healthy controls, 14 mild Alzheimer's disease, 14 amyloid-positive mild cognitive impairment). Neuroinflammation was assessed using [11C]PK11195 PET imaging, a marker of microglial activation. To quantify SVD, we assessed white matter hyperintensities (WMH), enlarged perivascular spaces, cerebral microbleeds and lacunes. Composite scores were calculated for global SVD burden, and SVD subtypes of hypertensive arteriopathy and cerebral amyloid angiopathy (CAA). General linear models examined associations between SVD and [11C]PK11195, adjusting for sex, age, education, cognition, scan interval, and corrected for multiple comparisons via false discovery rate (FDR). Dominance analysis directly compared the relative importance of hypertensive arteriopathy and CAA scores as predictors of [11C]PK11195. RESULTS Global [11C]PK11195 binding was associated with SVD markers, particularly in regions typical of hypertensive arteriopathy: deep microbleeds (β=0.63, F(1,35)=35.24, p<0.001), deep WMH (β=0.59, t=4.91, p<0.001). In dominance analysis, hypertensive arteriopathy score outperformed CAA in predicting [11C]PK11195 binding globally and in 28 out of 37 regions of interest, especially the medial temporal lobe (β=0.66-0.76, t=3.90-5.58, FDR-corrected p (pFDR)=<0.001-0.002) and orbitofrontal cortex (β=0.51-0.57, t=3.53-4.30, pFDR=0.001-0.004). CONCLUSION Microglial activation is associated with SVD, particularly with the hypertensive arteriopathy subtype of SVD. Although further research is needed to determine causality, our study suggests that targeting neuroinflammation might represent a novel therapeutic strategy for SVD.
Collapse
Affiliation(s)
- Audrey Low
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - Elijah Mak
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - Maura Malpetti
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Luca Passamonti
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Nicolas Nicastro
- Department of Psychiatry, University of Cambridge, Cambridge, UK
- Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland
| | - James D Stefaniak
- Division of Neuroscience and Experimental Psychology, The University of Manchester, Manchester, UK
- MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK
| | - George Savulich
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | | | - Li Su
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - James B Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Hugh S Markus
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - John T O'Brien
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| |
Collapse
|
118
|
Zhang C, Li W, Li S, Niu S, Wang X, Yu X, Zhang Z. Intracranial Large Artery Abnormalities and Association With Cerebral Small Vessel Disease in CADASIL. Front Neurol 2020; 11:726. [PMID: 33013610 PMCID: PMC7461925 DOI: 10.3389/fneur.2020.00726] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 06/15/2020] [Indexed: 11/13/2022] Open
Abstract
Background and objective: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited systemic arteriopathy, the classic feature of which is small vessel lesions. Studies on intracranial large arteries in CADASIL are not common. We aim to evaluate intracranial large arteries, describing the characteristics of large arteries in CADASIL and their association with cerebral small vessel associated lesions. Methods: Consecutive CADASIL patients from a single-center prospective cohort were analyzed. Brain magnetic resonance imaging and magnetic resonance angiography were performed to assess the intracranial large arteries and cerebral small vessels associated lesions' neuroimaging. Results: The study included 37 CADASIL patients. Of the patients, 28 of them (75.7%) had intracranial large artery abnormalities. Eighteen (48.6%) had congenital variations such as fenestration, vertebral artery (VA) hypoplasia and agenesis, or common trunk and fetus posterior cerebral artery. Seventeen (45.9%) had acquired anomalies such as arterial stenosis, prolongation, or tortuosity (seven of them had both congenital and acquired anomalies). CADASIL patients with anterior circulation middle cerebral artery (MCA) or internal cerebral artery (ICA) severe stenosis were more likely to have ipsilateral asymmetric white matter hyper-density (WMH) distribution. Patients with posterior circulation VA hypoplasia had a higher prevalence of posterior subcortical zone dominant WMH distribution. Conclusion: CADASIL patients can demonstrate various intracranial large artery abnormalities which might influence the development of microangiopathy. Assessment of great vessels seems essential in CADASIL.
Collapse
Affiliation(s)
- Chen Zhang
- Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - Wei Li
- Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - ShaoWu Li
- Department of Neuroimaging, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - SongTao Niu
- Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - XinGao Wang
- Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - Xueying Yu
- Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - ZaiQiang Zhang
- Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
119
|
Microangiopathie cérébrale: du diagnostic à la prise en charge small vessel disease of the brain: Diagnosis and management. Rev Med Interne 2020; 41:469-474. [PMID: 32718708 DOI: 10.1016/j.revmed.2020.04.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Revised: 02/18/2020] [Accepted: 04/21/2020] [Indexed: 11/24/2022]
Abstract
Small vessel disease of the brain is commonly identified among ageing people. It causes almost 25% of strokes and is associated with cognitive impairment and dementia as well as gait difficulties. Its diagnosis is usually made on MRI in the presence of deep white matter and basal ganglia hyperintensities as well as deep lacunar infarcts (lacunes), microbleeds and enlarged perivascular spaces. MRI is also of importance to identify the main differential diagnoses including inflammatory disorders, cerebral amyloid angiopathy and other genetic causes of microangiopathy. Small vessel disease is associated with the main vascular risk factors including notably age and hypertension but whether controlling these vascular risk factors is beneficial is still not clear. Here, we provide a comprehensive review underlining the main diagnostic features of cerebral microangiopathy and summarise the main therapeutic approaches (notably blood pressure normalisation and physical activity) used to control its development and prevent strokes as well as the development of cognitive involvement and gait impairment.
Collapse
|
120
|
Jensen-Kondering UR, Weiler C, Langguth P, Larsen N, Flüh C, Kuhlenbäumer G, Jansen O, Margraf NG. Clinical and radiological differences between patients with probable cerebral amyloid angiopathy and mixed cerebral microbleeds. J Neurol 2020; 267:3602-3608. [PMID: 32638111 PMCID: PMC7674181 DOI: 10.1007/s00415-020-10038-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 06/26/2020] [Accepted: 06/29/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND The key imaging features of cerebral amyloid angiopathy (CAA) are lobar, cortical, or cortico-subcortical microbleeds, macrohaemorrhages and cortical superficial siderosis (cSS). In contrast, hypertensive angiopathy is characterized by (micro) haemorrhages in the basal ganglia, thalami, periventricular white matter or the brain stem. Another distinct form of haemorrhagic microangiopathy is mixed cerebral microbleeds (mixed CMB) with features of both CAA and hypertensive angiopathy. The distinction between the two entities (CAA and mixed CMB) is clinically relevant because the risk of haemorrhage and stroke should be well balanced if oral anticoagulation is indicated in CAA patients. We aimed to comprehensively compare these two entities. METHODS Patients with probable CAA according to the modified Boston criteria and mixed CMB without macrohaemorrhage were retrospectively identified from our database. Comprehensive comparison regarding clinical and radiological parameters was performed between the two cohorts. RESULTS Patients with CAA were older (78 ± 8 vs. 74 ± 9 years, p = 0.036) and had a higher prevalence of cSS (19% vs. 4%, p = 0.027) but a lower prevalence of lacunes (73% vs. 50%, p = 0.018) and deep lacunes (23% vs. 51%, p = 0.0003) compared to patients with mixed CMB. Logistic regression revealed an association between the presence of deep lacunes and mixed CMB. The other collected parameters did not reveal a significant difference between the two groups. CONCLUSIONS CAA and mixed CMB demonstrate radiological differences in the absence of macrohaemorrhages. However, more clinically available biomarkers are needed to elucidate the contribution of CAA and hypertensive angiopathy in mixed CMB patients.
Collapse
Affiliation(s)
- Ulf R Jensen-Kondering
- Department of Radiology and Neuroradiology, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany.
| | - Caroline Weiler
- Department of Neurology, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany
| | - Patrick Langguth
- Department of Radiology and Neuroradiology, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany
| | - Naomi Larsen
- Department of Radiology and Neuroradiology, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany
| | - Charlotte Flüh
- Department of Neurosurgery, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany
| | - Gregor Kuhlenbäumer
- Department of Neurology, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany
| | - Olav Jansen
- Department of Radiology and Neuroradiology, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany
| | - Nils G Margraf
- Department of Neurology, University of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany
| |
Collapse
|
121
|
Hiremath N, Kate M, Mohimen A, Kesavadas C, Sylaja PN. Risk factors of white matter hyperintensities in South Asian patients with transient ischemic attack and minor stroke. Neuroradiology 2020; 62:1279-1284. [PMID: 32385557 DOI: 10.1007/s00234-020-02429-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2020] [Accepted: 04/02/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE Aging and increased burden of cardiovascular risk factors are associated with severity of white matter hyperintensity (WMH). We assessed the burden and risk factor profile of WMHs in South Asian patients with transient ischemic attack (TIA) and minor stroke. METHODS Patients with acute ischemic stroke with the National Institute of Health stroke scale (NIHSS) score ≤ 5 who underwent MRI were included. The severity of WMHs was assessed based on age-related white matter change (ARWMC) scale (0-30). A score of > 8 or more was considered moderate-severe involvement. Logistic regression analysis was performed to assess the association with risk factors. RESULTS A total of 424 patients with a mean ± SD age of 57.4 ± 14.5 years [females, 108 (25.5%)] were analyzed. Fifty-four (12.7%) patients had moderate or severe WMHs (ARWMC score > 8). Age (OR 1.03, 95% CI 1.01-1.06; p = 0.004), hypertension (OR 2.3, 95% CI 1.1-5.1; p = 0.03) and smoking tobacco (OR 2.8, 95% CI 1.4-5.6; p = 0.003) were independently associated with ARWMC score > 8. The median (IQR) regional score in patients with ARWMC score > 8 was maximum in frontal areas 4 (4-6, p < 0.0001) and parietooccipital areas 4.5(4-6, p < 0.0001). The presence of microbleeds (OR 6.3, 95% CI 3.1-12.7; p < 0.0001) was independently associated with ARWMC score > 8. CONCLUSION South Asian patients with TIA and minor stroke are relatively young, and few patients have moderate and severe WMHs. Hypertension and tobacco smoking increases the risk of WMH. Targeting modifiable risk factors may reduce the burden of WMHs and vascular dementia.
Collapse
Affiliation(s)
- Nikhil Hiremath
- Comprehensive Stroke Care Program, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, Kerala, 695011, India
| | - Mahesh Kate
- Department of Clinical Neurosciences, Alberta Health Services, Edmonton, Canada
| | - Aneesh Mohimen
- Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
| | - Chandrasekharan Kesavadas
- Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
| | - P N Sylaja
- Comprehensive Stroke Care Program, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, Kerala, 695011, India.
| |
Collapse
|
122
|
Shindo A, Ishikawa H, Ii Y, Niwa A, Tomimoto H. Clinical Features and Experimental Models of Cerebral Small Vessel Disease. Front Aging Neurosci 2020; 12:109. [PMID: 32431603 PMCID: PMC7214616 DOI: 10.3389/fnagi.2020.00109] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Accepted: 03/30/2020] [Indexed: 12/24/2022] Open
Abstract
Cerebral small vessel disease (SVD) refers to a group of disease conditions affecting the cerebral small vessels, which include the small arteries, arterioles, capillaries, and postcapillary venules in the brain. SVD is the primary cause of vascular cognitive impairment and gait disturbances in aged people. There are several types of SVD, though arteriolosclerosis, which is mainly associated with hypertension, aging, and diabetes mellitus, and cerebral amyloid angiopathy (CAA) comprise most SVD cases. The pathology of arteriolosclerosis-induced SVD is characterized by fibrinoid necrosis and lipohyalinosis, while CAA-associated SVD is characterized by progressive deposition of amyloid beta (Aβ) protein in the cerebral vessels. Brain magnetic resonance imaging (MRI) has been used for examination of SVD lesions; typical lesions are characterized by white matter hyperintensity, lacunar infarcts, enlargement of perivascular spaces (EPVS), microbleeds, cortical superficial siderosis (cSS), and cortical microinfarcts. The microvascular changes that occur in the small vessels are difficult to identify clearly; however, these consequent image findings can represent the SVD. There are two main strategies for prevention and treatment of SVD, i.e., pharmacotherapy and lifestyle modification. In this review, we discuss clinical features of SVD, experimental models replicating SVD, and treatments to further understand the pathological and clinical features of SVD.
Collapse
Affiliation(s)
- Akihiro Shindo
- Department of Neurology, Mie University Graduate School of Medicine, Mie University, Tsu, Japan
| | - Hidehiro Ishikawa
- Department of Neurology, Mie University Graduate School of Medicine, Mie University, Tsu, Japan
| | - Yuichiro Ii
- Department of Neurology, Mie University Graduate School of Medicine, Mie University, Tsu, Japan
| | - Atsushi Niwa
- Department of Neurology, Mie University Graduate School of Medicine, Mie University, Tsu, Japan
| | - Hidekazu Tomimoto
- Department of Neurology, Mie University Graduate School of Medicine, Mie University, Tsu, Japan
| |
Collapse
|
123
|
Lauer A, Ay H, Bianchi M, Charidimou A, Boulouis G, Ayres A, Vashkevich A, Schwab KM, Singhal AB, Viswanathan A, Rost NS, Goldstein JN, Rosand J, Schwamm LH, Greenberg SM, Gurol ME. Cerebral Small Vessel Diseases and Sleep Related Strokes. J Stroke Cerebrovasc Dis 2020; 29:104606. [PMID: 31937490 DOI: 10.1016/j.jstrokecerebrovasdis.2019.104606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 12/13/2019] [Accepted: 12/15/2019] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND AND PURPOSE Sleep related Stroke (SRS) is common and has been associated with cerebral small vessel diseases (SVD) in ischemic strokes (ISs). We tested the hypothesis that SRS is associated with SVD in both ischemic and hemorrhagic stroke. METHODS Prospectively collected data from patients consecutively enrolled after intracerebral hemorrhage (ICH) related to SVD or after IS were analyzed. Symptom onset was recorded as SRS versus awake. Each ICH was grouped according to lobar and deep locations. The IS cohort was etiologically characterized based on the Causative Classification of Stroke system. Frequencies of SRS within and between ICH and IS cohorts as well as its associations (etiology, risk factors) were analyzed. RESULTS We analyzed 1812 IS (mean age 67.9 years ± 15.9 years, 46.4% female) and 1038 ICH patients (mean age 72.5 years ± 13.0 years, 45.4% female). SRS was significantly more common among SVD-related ICH patients (n = 276, 26.6%) when compared to all IS (n = 363, 20.0%, P < .001) and in both, small artery occlusion (SAO) related IS and lobar ICH within the respective IS and ICH cohorts (16.3% SRS versus 9.1% awake for SAO within all IS, P < .001; and 57.1% SRS versus 47.7% awake for lobar bleeds within all ICH, P = .008). These associations remained significant after controlling for age, sex and risk factors. CONCLUSIONS SRS was associated with SVD. The SAO etiology and cerebral amyloid angiopathy related lobar ICH suggest that the presence of SVD can interact with sleep or arousal related hemodynamic changes to cause ischemic and hemorrhagic stroke.
Collapse
Affiliation(s)
- Arne Lauer
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Hakan Ay
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Matt Bianchi
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Andreas Charidimou
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Gregoire Boulouis
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Alison Ayres
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Anastasia Vashkevich
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Kristin M Schwab
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Aneesh B Singhal
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Anand Viswanathan
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Natalia S Rost
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Joshua N Goldstein
- Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | - Jonathan Rosand
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Lee H Schwamm
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Steven M Greenberg
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts
| | - Mahmut Edip Gurol
- Stroke Service, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
124
|
Abstract
PURPOSE OF REVIEW This article provides an overview of vascular cognitive impairment; discusses its epidemiology, subtypes, and associations with other neurodegenerative diseases; and reviews the diagnostic evaluation and management of these disorders. RECENT FINDINGS Cerebrovascular disease is a common cause of dementia and frequently coexists with neurodegenerative causes. The heterogeneity of mechanisms leading to vascular cognitive impairment makes developing unifying clinical and research criteria difficult. Recognizing the neuroimaging hallmarks of different forms of vascular cognitive impairment can allow for individualized treatment and management. In individuals with mild vascular cognitive impairment, aerobic exercise appears to be a promising treatment but requires further investigation. SUMMARY Vascular cognitive impairment can be caused by several mechanisms. While treating vascular risk factors is rational to prevent worsening of cognitive impairment, well-designed studies are needed to demonstrate efficacy.
Collapse
|
125
|
Affiliation(s)
- Marco Pasi
- From the Department of Neurology, Univervité de Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, France
| | - Charlotte Cordonnier
- From the Department of Neurology, Univervité de Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, France
| |
Collapse
|
126
|
Sorond FA, Whitehead S, Arai K, Arnold D, Carmichael ST, De Carli C, Duering M, Fornage M, Flores-Obando RE, Graff-Radford J, Hamel E, Hess DC, Ihara M, Jensen MK, Markus HS, Montagne A, Rosenberg G, Shih AY, Smith EE, Thiel A, Tse KH, Wilcock D, Barone F. Proceedings from the Albert Charitable Trust Inaugural Workshop on white matter and cognition in aging. GeroScience 2019; 42:81-96. [PMID: 31811528 DOI: 10.1007/s11357-019-00141-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 11/20/2019] [Indexed: 12/13/2022] Open
Abstract
This third in a series of vascular cognitive impairment (VCI) workshops, supported by "The Leo and Anne Albert Charitable Trust," was held from February 8 to 12 at the Omni Resort in Carlsbad, CA. This workshop followed the information gathered from the earlier two workshops suggesting that we focus more specifically on brain white matter in age-related cognitive impairment. The Scientific Program Committee (Frank Barone, Shawn Whitehead, Eric Smith, and Rod Corriveau) assembled translational, clinical, and basic scientists with unique expertise in acute and chronic white matter injury at the intersection of cerebrovascular and neurodegenerative etiologies. As in previous Albert Trust workshops, invited participants addressed key topics related to mechanisms of white matter injury, biomarkers of white matter injury, and interventions to prevent white matter injury and age-related cognitive decline. This report provides a synopsis of the presentations and discussions by the participants, including the existing knowledge gaps and the delineation of the next steps towards advancing our understanding of white matter injury and age-related cognitive decline. Workshop discussions and consensus resulted in action by The Albert Trust to (1) increase support from biannual to annual "White Matter and Cognition" workshops; (2) provide funding for two collaborative, novel research grants annually submitted by meeting participants; and (3) coordinate the formation of the "Albert Research Institute for White Matter and Cognition." This institute will fill a gap in white matter science, providing white matter and cognition communications, including annual updates from workshops and the literature and interconnecting with other Albert Trust scientific endeavors in cognition and dementia, and providing support for newly established collaborations between seasoned investigators and to the development of talented young investigators in the VCI-dementia (VCID) and white matter cognition arena.
Collapse
Affiliation(s)
- Farzaneh A Sorond
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA.
| | - Shawn Whitehead
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Ken Arai
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Douglas Arnold
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - S Thomas Carmichael
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Charles De Carli
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Marco Duering
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Myriam Fornage
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Rafael E Flores-Obando
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Jonathan Graff-Radford
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Edith Hamel
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - David C Hess
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Massafumi Ihara
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Majken K Jensen
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Hugh S Markus
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Axel Montagne
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Gary Rosenberg
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Andy Y Shih
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Eric E Smith
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Alex Thiel
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Kai Hei Tse
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Donna Wilcock
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| | - Frank Barone
- Department of Neurology, Division Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, 625 N. Michigan Ave, suite 1150, Chicago, IL, 60611, USA
| |
Collapse
|
127
|
Gurol ME, Biessels GJ, Polimeni JR. Advanced Neuroimaging to Unravel Mechanisms of Cerebral Small Vessel Diseases. Stroke 2019; 51:29-37. [PMID: 31752614 DOI: 10.1161/strokeaha.119.024149] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- M Edip Gurol
- From the Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.G.)
| | - Geert J Biessels
- Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, the Netherlands (G.J.B.)
| | - Jonathan R Polimeni
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown (J.R.P.).,Department of Radiology, Harvard Medical School, Boston, MA (J.R.P.).,Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA (J.P.R.)
| |
Collapse
|
128
|
Charidimou A, Frosch MP, Al-Shahi Salman R, Baron JC, Cordonnier C, Hernandez-Guillamon M, Linn J, Raposo N, Rodrigues M, Romero JR, Schneider JA, Schreiber S, Smith EE, van Buchem MA, Viswanathan A, Wollenweber FA, Werring DJ, Greenberg SM. Advancing diagnostic criteria for sporadic cerebral amyloid angiopathy: Study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0. Int J Stroke 2019; 14:956-971. [PMID: 31514686 DOI: 10.1177/1747493019855888] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
RATIONALE The Boston criteria are used worldwide for the in vivo diagnosis of cerebral amyloid angiopathy and are the basis for clinical decision-making and research in the field. Given substantial advances in cerebral amyloid angiopathy's clinical aspects and MRI biomarkers, we designed a multicenter study within the International cerebral amyloid angiopathy Association aimed at further validating the diagnostic accuracy of the Boston and potentially improving and updating them. AIM We aim to derive and validate an updated "version 2.0" of the Boston criteria across the spectrum of cerebral amyloid angiopathy-related presentations and MRI biomarkers. SAMPLE SIZE ESTIMATES Participating centers with suitable available data (see Methods) were identified from existing collaborations and an open invitation to the International Cerebral Amyloid Angiopathy Association emailing list. Our study sample will include: (1) a derivation cohort - Massachusetts General Hospital (MGH), Boston cases from inception to 2012 (∼150 patients); (2) temporal external validation cohort - MGH, Boston cases from 2012 to 2018 (∼100 patients); and (3) geographical external validation cohort - non-Boston cases (∼85 patients). METHODS AND DESIGN Multicenter collaborative study. We will collect and analyze data from patients' age ≥ 50 with any potential sporadic cerebral amyloid angiopathy-related clinical presentations (spontaneous intracerebral hemorrhage, transient focal neurological episodes and cognitive impairment), available brain MRI ("index test"), and histopathologic assessment for cerebral amyloid angiopathy ("reference standard" for diagnosis). Trained raters will assess MRI for all prespecified hemorrhagic and non-hemorrhagic small vessel disease markers of interest, according to validated criteria and a prespecified protocol, masked to clinical and histopathologic features. Brain tissue samples will be rated for cerebral amyloid angiopathy, defined as Vonsattel grade ≥2 for whole brain autopsies and ≥1 for cortical biopsies or hematoma evacuation. Based on our estimated available sample size, we will undertake pre-specified cohort splitting as above. We will: (a) pre-specify variables and statistical cut-offs; (b) examine univariable and multivariable associations; and (c) then assess classification measures (sensitivity, specificity etc.) for each MRI biomarker individually, in relation to the cerebral amyloid angiopathy diagnosis reference standard on neuropathology in a derivation cohort. The MRI biomarkers strongly associated with cerebral amyloid angiopathy diagnosis will be selected for inclusion in provisional (probable and possible cerebral amyloid angiopathy) Boston criteria v2.0 and validated using appropriate metrics and models. STUDY OUTCOMES Boston criteria v2.0 for clinical cerebral amyloid angiopathy diagnosis. DISCUSSION This work aims to potentially update and improve the diagnostic test accuracy of the Boston criteria for cerebral amyloid angiopathy and to provide wider validation of the criteria in a large sample. We envision that this work will meet the needs of clinicians and investigators and help accelerate progress towards better treatment of cerebral amyloid angiopathy.
Collapse
Affiliation(s)
- Andreas Charidimou
- Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Matthew P Frosch
- C.S. Kubik Laboratory of Neuropathology, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
| | | | - Jean-Claude Baron
- Department of Neurology, Sainte-Anne Hospital, Université Paris Descartes, INSERM U894, Paris, France
| | - Charlotte Cordonnier
- Department of Neurology, INSERM U1171-Degenerative and Vascular Cognitive Disorders, CHU Lille, University of Lille, Lille, France
| | - Mar Hernandez-Guillamon
- Neurovascular Research Laboratory, Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Jennifer Linn
- Department of Neuroradiology, University Hospital Carl Gustav Carus', Technische Universität Dresden, Dresden, SN, Germany
| | - Nicolas Raposo
- Department of Neurology, Toulouse University Medical Center, Toulouse, France
| | - Mark Rodrigues
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Jose Rafael Romero
- Department of Neurology, Boston University School of Medicine, MA and the Framingham Heart Study, MA, USA
| | - Julie A Schneider
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
| | | | - Eric E Smith
- Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Canada
| | - Mark A van Buchem
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Anand Viswanathan
- Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Frank A Wollenweber
- Institute for Stroke and Dementia Research, Ludwig Maximilians University, Munich, Germany
| | - David J Werring
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, University College London Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK
| | - Steven M Greenberg
- Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | | |
Collapse
|
129
|
Schreiber S, Wilisch-Neumann A, Schreiber F, Assmann A, Scheumann V, Perosa V, Jandke S, Mawrin C, Carare RO, Werring DJ. Invited Review: The spectrum of age-related small vessel diseases: potential overlap and interactions of amyloid and nonamyloid vasculopathies. Neuropathol Appl Neurobiol 2019; 46:219-239. [PMID: 31386773 DOI: 10.1111/nan.12576] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 07/10/2019] [Accepted: 07/11/2019] [Indexed: 12/12/2022]
Abstract
Deep perforator arteriopathy (DPA) and cerebral amyloid angiopathy (CAA) are the commonest known cerebral small vessel diseases (CSVD), which cause ischaemic stroke, intracebral haemorrhage (ICH) and vascular cognitive impairment (VCI). While thus far mainly considered as separate entities, we here propose that DPA and CAA share similarities, overlap and interact, so that 'pure' DPA or CAA are extremes along a continuum of age-related small vessel pathologies. We suggest blood-brain barrier (BBB) breakdown, endothelial damage and impaired perivascular β-amyloid (Aβ) drainage are hallmark common mechanisms connecting DPA and CAA. We also suggest a need for new biomarkers (e.g. high-resolution imaging) to deepen understanding of the complex relationships between DPA and CAA.
Collapse
Affiliation(s)
- S Schreiber
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Magdeburg, Germany.,Center for behavioral brain sciences (CBBS), Magdeburg, Germany
| | - A Wilisch-Neumann
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Magdeburg, Germany
| | - F Schreiber
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Magdeburg, Germany
| | - A Assmann
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Magdeburg, Germany
| | - V Scheumann
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany
| | - V Perosa
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Magdeburg, Germany
| | - S Jandke
- Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Magdeburg, Germany
| | - C Mawrin
- Department of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany
| | - R O Carare
- Faculty of Medicine, University of Southampton, Southampton, UK
| | - D J Werring
- Stroke Research Centre, Department of Brain Repair & Rehabilitation, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
| |
Collapse
|
130
|
Su N, Liang X, Yao M, Zhou LX, Wang Q, Jin ZY, Zhang SY, Cui LY, Gong G, Zhu YC, Ni J. Cerebral Microbleeds Correlated with White Matter and Hippocampal Volumes in Community-Dwelling Populations. J Alzheimers Dis 2019; 71:559-567. [PMID: 31424402 DOI: 10.3233/jad-190454] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Few studies have investigated the correlation between cerebral microbleeds (CMBs), a hemorrhagic imaging marker of cerebral small vessel disease (CSVD), and brain volume. OBJECTIVE We investigated the association between the burden and locations of CMBs and brain volume in community-dwelling populations. METHODS Data were obtained from 1,029 participants who underwent brain magnetic resonance imaging (MRI) and APOE genotyping. Volumes of the whole brain, subcortical white matter (WM), cortical gray matter (GM), and hippocampus were extracted. Linear regression models were used to investigate the relationship between the CMB burden and their location with structural changes. RESULTS Regarding burden, participants with≥3 CMBs had significantly lower whole brain (β= -1.124, p = 0.0133), subcortical WM (β= -1.020, p = 0.0043), and hippocampus (β= -0.015, p = 0.0088) volumes than those without CMBs. Regarding location and burden, the presence of≥3 strictly lobar CMBs was negatively associated with whole brain volume (β= -2.838, p = 0.0088). Additionally, higher CMB burdens in strictly lobar locations or deep/mixed locations were associated with lower subcortical WM volume (β= -1.689, p = 0.0482; β= -0.872, p = 0.0464, respectively). Finally, the presence of≥3 deep/mixed CMBs was associated with lower hippocampus volume (β= -0.018, p = 0.0088), and these associations were independent of other ischemic markers of CSVD. However, the CMB burden and distributional pattern did not correlate with cortical GM volumes. CONCLUSION A higher CMB burden, in specific locations, is associated with decreased brain volumes in community-dwelling populations.
Collapse
Affiliation(s)
- Ning Su
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xinyu Liang
- State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China
| | - Ming Yao
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Li-Xin Zhou
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Quan Wang
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Zheng-Yu Jin
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shu-Yang Zhang
- Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Li-Ying Cui
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Gaolang Gong
- State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China
| | - Yi-Cheng Zhu
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jun Ni
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
131
|
Brain White Matter: A Substrate for Resilience and a Substance for Subcortical Small Vessel Disease. Brain Sci 2019; 9:brainsci9080193. [PMID: 31398858 PMCID: PMC6721396 DOI: 10.3390/brainsci9080193] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 07/31/2019] [Accepted: 08/05/2019] [Indexed: 01/01/2023] Open
Abstract
Age-related brain white matter disease is a form of small vessel disease (SVD) that may be associated with lacunar and other small subcortical infarcts, cerebral microbleeds, and perivascular spaces. This common form of cerebrovascular disease may manifest clinically as cognitive impairment of varying degrees and difficulty with mobility. Whereas some persons show cognitive decline and mobility failure when there are brain white matter hyperintensities (WMH) and acute stroke, others recover, and not everyone with brain white matter disease is disabled. Thus, repair or compensation of brain white matter may be possible, and furthermore, certain vascular risks, such as raised blood pressure, are targets for prevention of white matter disease or are administered to reduce the burden of such disease. Vascular risk modification may be useful, but alone may not be sufficient to prevent white matter disease progression. In this chapter, we specifically focus on WMH of vascular origin and explore white matter development, plasticity, and enduring processes of myelination across the health span in the context of experimental and human data, and compare and contrast resilient brain white matter propensity to a diseased white matter state. We conclude with thoughts on novel ways one might study white matter resilience, and predict future healthy cognitive and functional outcomes.
Collapse
|
132
|
Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, Schwarz CG, Brown RD, Rabinstein AA, Gunter JL, Senjem ML, Przybelski SA, Lesnick T, Ward C, Mielke MM, Lowe VJ, Petersen RC, Kremers WK, Kantarci K, Jack CR, Vemuri P. White matter hyperintensities: relationship to amyloid and tau burden. Brain 2019; 142:2483-2491. [PMID: 31199475 PMCID: PMC6658846 DOI: 10.1093/brain/awz162] [Citation(s) in RCA: 148] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 04/02/2019] [Accepted: 04/18/2019] [Indexed: 01/10/2023] Open
Abstract
Although white matter hyperintensities have traditionally been viewed as a marker of vascular disease, recent pathology studies have found an association between white matter hyperintensities and Alzheimer's disease pathologies. The objectives of this study were to investigate the topographic patterns of white matter hyperintensities associated with Alzheimer's disease biomarkers measured using PET. From the population-based Mayo Clinic Study of Aging, 434 participants without dementia (55% male) with FLAIR and gradient recall echo MRI, tau-PET (AV-1451) and amyloid-PET scans were identified. A subset had cerebral microbleeds detected on T2* gradient recall echo scans. White matter hyperintensities were semi-automatically segmented using FLAIR MRI in participant space and normalized to a custom template. We used statistical parametric mapping 12-based, voxel-wise, multiple-regression analyses to detect white matter hyperintense regions associated with Alzheimer's biomarkers (global amyloid from amyloid-PET and meta-regions of interest tau uptake from tau-PET) after adjusting for age, sex and hypertension. For amyloid associations, we additionally adjusted for tau and vice versa. Topographic patterns of amyloid-associated white matter hyperintensities included periventricular white matter hyperintensities (frontal and parietal lobes). White matter hyperintense volumes in the detected topographic pattern correlated strongly with lobar cerebral microbleeds (P < 0.001, age and sex adjusted Cohen's d = 0.703). In contrast, there were no white matter hyperintense regions significantly associated with increased tau burden using voxel-based analysis or region-specific analysis. Among non-demented elderly, amyloid load correlated with a topographic pattern of white matter hyperintensities. Further, the amyloid-associated, white matter hyperintense regions strongly correlated with lobar cerebral microbleeds suggesting that cerebral amyloid angiopathy contributes to the relationship between amyloid and white matter hyperintensities. The study did not support an association between increased tau burden and white matter hyperintense burden.
Collapse
Affiliation(s)
| | | | - David S Knopman
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
| | | | - Robert D Brown
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
| | | | | | | | - Scott A Przybelski
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
| | - Timothy Lesnick
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
| | - Chadwick Ward
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Michelle M Mielke
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
| | - Val J Lowe
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | | | - Walter K Kremers
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
| | - Kejal Kantarci
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Clifford R Jack
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | | |
Collapse
|
133
|
Park YS, Chung MS, Choi BS. MRI Assessment of Cerebral Small Vessel Disease in Patients with Spontaneous Intracerebral Hemorrhage. Yonsei Med J 2019; 60:774-781. [PMID: 31347333 PMCID: PMC6660438 DOI: 10.3349/ymj.2019.60.8.774] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 05/28/2019] [Accepted: 06/04/2019] [Indexed: 11/27/2022] Open
Abstract
PURPOSE Cerebral small vessel disease (SVD) is known to be associated with ischemic stroke, intracerebral hemorrhage (ICH), and cognitive impairment. In this retrospective observational study, we explored SVD markers on MRI relevant to spontaneous ICH. MATERIALS AND METHODS The ICH group consisted of 150 consecutive patients with a first primary parenchymal ICH, and the control group consisted of 271 age- and sex-matched individuals who underwent brain MRI in a health care center. We compared cerebral microbleeds (CMBs), white matter hyperintensities (WMHs), enlarged perivascular space (EPVS), and lacunae in the ICH and control groups. RESULTS A total of 1278 CMB lesions were identified in 121 of the 150 patients in the ICH group (80.6%), while 77 CMB lesions were found in 32 of the 271 individuals in the control group (11.8%). WMH and EPVS were more severe and lacunae were more frequent in the ICH patients than in the control group. When receiver operating characteristic (ROC) curves were plotted, number of CMBs most significantly predicted ICH. All imaging markers were significantly associated with ICH in every age group. The location of CMBs coincided with the location of ICH, and ICH volume correlated with CMB count. CONCLUSION All MRI markers for SVD were worse in ICH patients than in healthy controls, and these markers were prominent even in young ICH patients. Lacunae, WMH, EPVS, and CMB should be considered as factors related with spontaneous ICH.
Collapse
Affiliation(s)
- Yong Sook Park
- Department of Neurosurgery, Chung-Ang University College of Medicine, Seoul, Korea.
| | - Mi Sun Chung
- Department of Radiology, Chung-Ang University College of Medicine, Seoul, Korea
| | - Byung Sun Choi
- Department of Preventive Medicine, Chung-Ang University College of Medicine, Seoul, Korea
| |
Collapse
|
134
|
Das AS, Regenhardt RW, Feske SK, Gurol ME. Treatment Approaches to Lacunar Stroke. J Stroke Cerebrovasc Dis 2019; 28:2055-2078. [PMID: 31151838 PMCID: PMC7456600 DOI: 10.1016/j.jstrokecerebrovasdis.2019.05.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 04/15/2019] [Accepted: 05/02/2019] [Indexed: 12/12/2022] Open
Abstract
Lacunar strokes are appropriately named for their ability to cavitate and form ponds or "little lakes" (Latin: lacune -ae meaning pond or pit is a diminutive form of lacus meaning lake). They account for a substantial proportion of both symptomatic and asymptomatic ischemic strokes. In recent years, there have been several advances in the management of large vessel occlusions. New therapies such as non-vitamin K antagonist oral anticoagulants and left atrial appendage closure have recently been developed to improve stroke prevention in atrial fibrillation; however, the treatment of small vessel disease-related strokes lags frustratingly behind. Since Fisher characterized the lacunar syndromes and associated infarcts in the late 1960s, there have been no therapies specifically targeting lacunar stroke. Unfortunately, many therapeutic agents used for the treatment of ischemic stroke in general offer only a modest benefit in reducing recurrent stroke while adding to the risk of intracerebral hemorrhage and systemic bleeding. Escalation of antithrombotic treatments beyond standard single antiplatelet agents has not been effective in long-term lacunar stroke prevention efforts, unequivocally increasing intracerebral hemorrhage risk without providing a significant benefit. In this review, we critically review the available treatments for lacunar stroke based on evidence from clinical trials. For several of the major drugs, we summarize the adverse effects in the context of this unique patient population. We also discuss the role of neuroprotective therapies and neural repair strategies as they may relate to recovery from lacunar stroke.
Collapse
Affiliation(s)
- Alvin S Das
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Robert W Regenhardt
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Steven K Feske
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Mahmut Edip Gurol
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
135
|
Gyanwali B, Vrooman H, Venketasubramanian N, Wong TY, Cheng CY, Chen C, Hilal S. Cerebral Small Vessel Disease and Enlarged Perivascular Spaces-Data From Memory Clinic and Population-Based Settings. Front Neurol 2019; 10:669. [PMID: 31293506 PMCID: PMC6603207 DOI: 10.3389/fneur.2019.00669] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Accepted: 06/07/2019] [Indexed: 01/27/2023] Open
Abstract
Background: Enlarged perivascular spaces (ePVS) are common finding on magnetic resonance imaging (MRI) in elderly. ePVS are thought to be associated with cerebral small vessel disease (SVD) such as white matter hyperintensities (WMH), lacunes, and cerebral microbleeds (CMBs). However, the different location of SVD and its relationship to ePVS distribution requires further investigation. Objective: To study the association between location and severity of SVD with ePVS from memory clinic and population-based settings. Methods: This study includes patients from an ongoing memory clinic based case-control study and participants from the population-based: Epidemiology of Dementia in Singapore study (EDIS). All participants underwent a comprehensive standardized evaluation including physical, medical and neuropsychological assessment and a brain MRI. CMBs and lacune location were categorized into strictly lobar, strictly deep and mixed, and ePVS location into centrum semiovale and basal ganglia. WMH volume was automatically segmented and was classified into anterior and posterior distribution. Negative binomial regression models were constructed to analyse associations between SVD and ePVS and the rate ratios (RR) and 95% confidence intervals (CI) were reported. Results: Of 375 patients (median age = 73 years) from memory clinic and 583 participants (median age = 70 years) from EDIS, the median total ePVS count was 17.0 and 7.0, respectively. Increased severity of SVD was not associated with total ePVS counts in both memory clinic and EDIS study. Analysis with the location of SVD and ePVS also showed similar results. However, in EDIS study, presence of ≥2 lacunes [RR = 1.61, 95% CI = 1.3, 2.30, p = 0.009], presence of ≥2 CMBs [RR = 1.40, 95% CI = 1.08, 1.83, p = 0.012], and higher volume of WMH [RR = 1.41, 95% CI = 1.10, 1.81, p = 0.006] were associated with basal ganglia ePVS independent of age, gender and vascular risk factors. Conclusion: In this study, we found that the ePVS were not associated with the location and severity of SVD in the memory-clinic patients. However, only severity of SVD was associated with basal ganglia ePVS in the population-based setting. Our findings will need to be studied further in different cohorts so as to understand the mechanism underlying different SVD types in subclinical and clinical phases as well as for predicting cognitive decline.
Collapse
Affiliation(s)
- Bibek Gyanwali
- Memory Aging and Cognition Centre, National University Health System, Singapore, Singapore.,Department of Pharmacology, National University of Singapore, Singapore, Singapore
| | - Henri Vrooman
- Departments of Radiology and Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | | | - Tien Yin Wong
- Singapore National Eye Center, Singapore Eye Research Institute, Singapore, Singapore
| | - Ching-Yu Cheng
- Singapore National Eye Center, Singapore Eye Research Institute, Singapore, Singapore
| | - Christopher Chen
- Memory Aging and Cognition Centre, National University Health System, Singapore, Singapore.,Department of Pharmacology, National University of Singapore, Singapore, Singapore
| | - Saima Hilal
- Memory Aging and Cognition Centre, National University Health System, Singapore, Singapore.,Department of Pharmacology, National University of Singapore, Singapore, Singapore.,Departments of Epidemiology and Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
| |
Collapse
|
136
|
Charidimou A, Zonneveld HI, Shams S, Kantarci K, Shoamanesh A, Hilal S, Yates PA, Boulouis G, Na HK, Pasi M, Biffi A, Chai YL, Chong JR, Wahlund LO, Clifford JR, Chen C, Gurol ME, Goldstein JN, Na DL, Barkhof F, Seo SW, Rosand J, Greenberg SM, Viswanathan A. APOE and cortical superficial siderosis in CAA: Meta-analysis and potential mechanisms. Neurology 2019; 93:e358-e371. [PMID: 31243071 DOI: 10.1212/wnl.0000000000007818] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 03/11/2019] [Indexed: 01/01/2023] Open
Abstract
OBJECTIVE To assess potential mechanisms of cortical superficial siderosis (cSS), a central MRI biomarker in cerebral amyloid angiopathy (CAA), we performed a collaborative meta-analysis of APOE associations with cSS presence and severity. METHODS We pooled data from published studies reporting APOE genotype and MRI assessment of cSS in 3 distinct settings: (1) stroke clinic patients with symptomatic CAA (i.e., lobar intracerebral hemorrhage, transient focal neurologic episodes) according to the Boston criteria; (2) memory clinic patients; and (3) population-based studies. We compared cSS presence and severity (focal or disseminated vs no cSS) in participants with ε2+ or ε4+ genotype vs the ε3/ε3 genotype, by calculating study-specific and random effects pooled, unadjusted odds ratios (ORs). RESULTS Thirteen studies fulfilled inclusion criteria: 7 memory clinic cohorts (n = 2,587), 5 symptomatic CAA cohorts (n = 402), and 1 population-based study (n = 1,379). There was no significant overall association between APOE ε4+ and cSS presence or severity. When stratified by clinical setting, APOE ε4+ was associated with cSS in memory clinic (OR 2.10; 95% confidence interval [CI] 1.11-3.99) but not symptomatic CAA patients. The pooled OR showed significantly increased odds of having cSS for APOE ε2+ genotypes (OR 2.42, 95% CI 1.48-3.95) in both patient populations. This association was stronger for disseminated cSS in symptomatic CAA cohorts. In detailed subgroup analyses, APOE ε2/ε2 and APOE ε2/ε4 genotypes were most consistently and strongly associated with cSS presence and severity. CONCLUSION CAA-related vasculopathic changes and fragility associated with APOE ε2+ allele might have a biologically meaningful role in the pathophysiology and severity of cSS.
Collapse
Affiliation(s)
- Andreas Charidimou
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston.
| | - Hazel I Zonneveld
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Sara Shams
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Kejal Kantarci
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Ashkan Shoamanesh
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Saima Hilal
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Paul A Yates
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Gregoire Boulouis
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Han Kyu Na
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Marco Pasi
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Allesandro Biffi
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Yuek Ling Chai
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Joyce Ruifen Chong
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Lars-Olof Wahlund
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Jack R Clifford
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Christopher Chen
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - M Edip Gurol
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Joshua N Goldstein
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Duk L Na
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Frederik Barkhof
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Sang Won Seo
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Jonathan Rosand
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Steven M Greenberg
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Anand Viswanathan
- From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston
| |
Collapse
|
137
|
Xu M, Cheng Y, Song Q, Yuan R, Zhang S, Hao Z, Liu M. Total Burden of Cerebral Small Vessel Disease in Recurrent ICH versus First-ever ICH. Aging Dis 2019; 10:570-577. [PMID: 31165001 PMCID: PMC6538213 DOI: 10.14336/ad.2018.0804] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 08/04/2018] [Indexed: 02/05/2023] Open
Abstract
The relationship between recurrent intracerebral hemorrhage (ICH) and total burden of cerebral small vessel disease (CSVD) is not completely investigated. We aimed to study whether recurrent intracerebral hemorrhage (ICH) had higher CSVD score than first-ever ICH. Lacunes, white matter hyperintensities (WMH), cerebral microbleeds (CMBs), enlarged perivascular spaces (EPVS), cortical superficial siderosis (cSS) and CSVD score were rated on brain magnetic resonance imaging (MRI) in primary ICH patients. Recurrent ICHs were confirmed by reviewing the medical records and MRI scans. Mixed hematomas were defined as follows: deep + lobar, deep + cerebellar, or deep + lobar + cerebellar. Of the 184 patients with primary ICH enrolled (mean age, 61.0 years; 75.5% men), recurrent ICH was present in 45 (24.5%) patients; 26.1% (48/184) had ≥2 hematomas, 93.8% (45/48) of which exhibited recurrent ICH. Mixed hematomas were identified in 8.7% (16/184) of patients and bilateral hematomas in 17.9% (33/184). All mixed hematomas and bilateral hematomas were from cases of recurrent ICH. Patients with mixed etiology-ICH were more likely to have recurrent ICH than patients with cerebral amyloid angiopathy (CAA) or hypertensive angiopathy (HA)-related ICH (36.8% vs17.8%, p=0.008). Multivariate ordinal regression analysis showed that the presence of recurrent ICH (p=0.001), ≥2 hematomas (p=0.002), mixed hematomas (p<0.00001), and bilateral hematomas (p=0.002) were separately significantly associated with a high CSVD score. Recurrent ICH occurs mostly among patients with mixed etiology-ICH and is associated with a higher CSVD burden than first-ever ICH, which needs to be verified by future larger studies.
Collapse
Affiliation(s)
- Mangmang Xu
- Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University.Chengdu, 610041, Sichuan Province, China
| | - Yajun Cheng
- Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University.Chengdu, 610041, Sichuan Province, China
| | - Quhong Song
- Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University.Chengdu, 610041, Sichuan Province, China
| | - Ruozhen Yuan
- Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University.Chengdu, 610041, Sichuan Province, China
| | - Shuting Zhang
- Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University.Chengdu, 610041, Sichuan Province, China
| | - Zilong Hao
- Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University.Chengdu, 610041, Sichuan Province, China
| | - Ming Liu
- Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University.Chengdu, 610041, Sichuan Province, China
| |
Collapse
|
138
|
Regenhardt RW, Das AS, Ohtomo R, Lo EH, Ayata C, Gurol ME. Pathophysiology of Lacunar Stroke: History's Mysteries and Modern Interpretations. J Stroke Cerebrovasc Dis 2019; 28:2079-2097. [PMID: 31151839 DOI: 10.1016/j.jstrokecerebrovasdis.2019.05.006] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 04/13/2019] [Accepted: 05/04/2019] [Indexed: 01/13/2023] Open
Abstract
Since the term "lacune" was adopted in the 1800s to describe infarctions from cerebral small vessels, their underlying pathophysiological basis remained obscure until the 1960s when Charles Miller Fisher performed several autopsy studies of stroke patients. He observed that the vessels displayed segmental arteriolar disorganization that was associated with vessel enlargement, hemorrhage, and fibrinoid deposition. He coined the term "lipohyalinosis" to describe the microvascular mechanism that engenders small subcortical infarcts in the absence of a compelling embolic source. Since Fisher's early descriptions of lipohyalinosis and lacunar stroke (LS), there have been many advancements in the understanding of this disease process. Herein, we review lipohyalinosis as it relates to modern concepts of cerebral small vessel disease (cSVD). We discuss clinical classifications of LS as well as radiographic definitions based on modern neuroimaging techniques. We provide a broad and comprehensive overview of LS pathophysiology both at the vessel and parenchymal levels. We also comment on the role of biomarkers, the possibility of systemic disease processes, and advancements in the genetics of cSVD. Lastly, we assess preclinical models that can aid in studying LS disease pathogenesis. Enhanced understanding of this highly prevalent disease will allow for the identification of novel therapeutic targets capable of mitigating disease sequelae.
Collapse
Affiliation(s)
- Robert W Regenhardt
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Alvin S Das
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Ryo Ohtomo
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Eng H Lo
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Cenk Ayata
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Mahmut Edip Gurol
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
139
|
Chen SJ, Tsai HH, Tsai LK, Tang SC, Lee BC, Liu HM, Yen RF, Jeng JS. Advances in cerebral amyloid angiopathy imaging. Ther Adv Neurol Disord 2019; 12:1756286419844113. [PMID: 31105769 PMCID: PMC6501479 DOI: 10.1177/1756286419844113] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Accepted: 03/25/2019] [Indexed: 11/16/2022] Open
Abstract
Cerebral amyloid angiopathy (CAA) is a cerebral small vessel disease caused by β -amyloid (Aβ) deposition at the leptomeningeal vessel walls. It is a common cause of spontaneous intracerebral hemorrhage and a frequent comorbidity in Alzheimer’s disease. The high recurrent hemorrhage rate in CAA makes it very important to recognize this disease to avoid potential harmful medication. Imaging studies play an important role in diagnosis and research of CAA. Conventional computed tomography and magnetic resonance imaging (MRI) methods reveal anatomical alterations, and remains as the most reliable tool in identifying CAA according to modified Boston criteria. The vascular injuries of CAA result in both hemorrhagic and ischemic manifestations and related structural changes on MRI, including cerebral microbleeds, cortical superficial siderosis, white matter hyperintensity, MRI-visible perivascular spaces, and cortical microinfarcts. As imaging techniques advance, not only does the resolution of conventional imaging improve, but novel skills in functional and molecular imaging studies also enable in vivo analysis of vessel physiological changes and underlying pathology. These modern tools help in early detection of CAA and may potentially serve as sensitive outcome markers in future clinical trials. In this article, we reviewed past studies of CAA focusing on utilization of various conventional and novel imaging techniques in both research and clinical aspects.
Collapse
Affiliation(s)
- Szu-Ju Chen
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan Department of Neurology, En Chu Kong Hospital, New Taipei City, Taiwan
| | - Hsin-Hsi Tsai
- Department of Neurology, National Taiwan University Hospital Bei-Hu Branch, No. 87, Neijiang Street, Taipei, 10845, Taiwan
| | - Li-Kai Tsai
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan
| | - Sung-Chun Tang
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan
| | - Bo-Chin Lee
- Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan
| | - Hon-Man Liu
- Department of Medical Imaging, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan
| | - Ruoh-Fang Yen
- Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Jiann-Shing Jeng
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan
| |
Collapse
|
140
|
Wang D, Norton C, Helenius J, Xu X, Liu M, Selim M, Lioutas VA. Progression of White Matter Injury After Intracerebral Hemorrhage: A Magnetic Resonance Imaging Study. World Neurosurg 2019; 126:e534-e544. [PMID: 30831290 DOI: 10.1016/j.wneu.2019.02.089] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 02/07/2019] [Accepted: 02/08/2019] [Indexed: 02/05/2023]
Abstract
BACKGROUND White matter injury (WMI) has been observed after experimental intracerebral hemorrhage (ICH). The supporting clinical data have been sparse. We assessed the presence, extent, and progression of WMI in patients with ICH. METHODS We performed a retrospective review of data from 65 consecutive patients with spontaneous supratentorial ICH who had undergone baseline brain magnetic resonance imaging (MRI) within 7 days of ICH onset and repeat MRI afterward. We used the Fazekas scale (FZKS) to grade the severity of WMI. The clinical and imaging characteristics of the patients with and without WMI progression (WMIP) were compared using uni- and multivariate logistic regression analyses. RESULTS We observed WMIP in 23 patients (35.4%). WMIP was noted in both hemispheres but more commonly ipsilateral to the ICH (33% vs. 21%). The mean total FZKS score had increased from 3 (interquartile range [IQR], 1-4) at baseline to 4 (IQR, 2-5) on repeat MRI (P < 0.0001). Patients with lobar ICH had a greater median FZKS score than those with deep ICH (median, 3; IQR, 2-4; vs. 1.5, IQR, 1-3.25; P = 0.027). The baseline parenchymal ICH volume (odds ratio [OR], 1.067; 95% confidence interval [CI], 1.018-1.119; P = 0.007) and ventricular volume on baseline MRI (OR, 1.073; 95% CI, 1.019-1.130; P = 0.007) were predictors of WMIP after adjustment. Multivariate analyses showed an independent association between WMIP and unfavorable 3-month outcomes (OR, 5.196; 95% CI, 1.059-25.483; P = 0.042). CONCLUSIONS WMI will progress over time in patients with ICH, and WMIP has been associated with worse outcomes. This novel finding could represent a potential therapeutic target. Future prospective larger studies are needed to confirm our findings.
Collapse
Affiliation(s)
- Deren Wang
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China; Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Casey Norton
- Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Johanna Helenius
- Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Xiaomeng Xu
- Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
| | - Ming Liu
- Department of Neurology, Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China
| | - Magdy Selim
- Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
| | - Vasileios-Arsenios Lioutas
- Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
141
|
Clinical and neuropathologic analysis of intracerebral hemorrhage in patients with cerebral amyloid angiopathy. Clin Neurol Neurosurg 2018; 176:110-115. [PMID: 30554091 DOI: 10.1016/j.clineuro.2018.11.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 11/12/2018] [Accepted: 11/25/2018] [Indexed: 11/21/2022]
Abstract
OBJECTIVE To evaluate the clinical and histopathological features of elderly patients with subcortical intracerebral hemorrhage (ICH), and to analyze the presence of cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD) type pathologic changes using amyloid beta (Aβ) and tau immunohistochemistry. PATIENTS AND METHODS We retrospectively analyzed cases satisfying the Boston criteria for CAA among patients with subcortical hemorrhage who underwent surgical removal by craniotomy at our hospital. Surgical specimens were subjected to hematoxylin and eosin (HE) staining as well as immunostaining. RESULTS A total of 54 patients were included in this study, with a mean age of 74.5 years (range: 72.5-76.5 years, 95% confidence interval [CI]; 51% female). Of these 54 patients, 31 (57%) were hypertensive, 18 (33%) were undergoing antithrombotic therapy, and 12 (22%) had dementia. Strong immunoreactivity for Aβ40 in the cerebral vessels was observed in 30 patients (55.6%), and among these, 27 patients (90%) also showed strong immunoreactivity for Aβ42. Among the 54 patients, 25 (46%) exhibited AD characteristics, including Aβ-positive senile plaques and AT8-positive neurons. Multivariate analysis revealed that strong Aβ40 immunoreactivity in the cerebral vessels was associated with older patients, females, lack of high blood pressure, and the presence of AT8-positive neurons. CONCLUSION CAA patients with strong Aβ40 deposition in the cerebral vessels were associated with subcortical hemorrhage in our cohort. Future studies should investigate the pathomechanism of ICH in individuals with CAA.
Collapse
|
142
|
Lee YM, Koo HW, Kang HK, Kim JW, Han SR, Yoon SW, Choi CY, Sohn MJ, Lee CH. The Prevalence and Characterization of Cerebral Microbleeds in Young People Having Intracerebral Hemorrhage. J Cerebrovasc Endovasc Neurosurg 2018; 20:112-119. [PMID: 30370245 PMCID: PMC6196144 DOI: 10.7461/jcen.2018.20.2.112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 04/20/2018] [Accepted: 06/01/2018] [Indexed: 11/23/2022] Open
Abstract
Objective Cerebral microbleeds (CMBs) are known as the neuroimaging markers of risk in stroke and dementia. Many studies on CMBs in elderly patients with hemorrhagic or ischemic stroke have been reported; however, reports on CMBs in young populations with intracerebral hemorrhage (ICH) are lacking. Materials and Methods A total of 272 patients aged 18–54 years presented to our hospital with ICH between December 2009 and August 2017. Among these, CMB presence, count, and topography with respect to ICH were evaluated on magnetic resonance imaging (MRI) gradient echo images (GREs). We also evaluated the prevalence and risk factors of CMBs. Results Among 272 patients, only 66 underwent GRE T2-weighted MRI. CMBs were detected in 40 patients (61%), with 29 (73%) being of the multifocal type. Among the 219 CMBs, 150 (68.5%) were of the deep type and 69 (31.5%) of the lobar type. CMB prevalence was higher in men. In multivariate logistic regression analysis, history of hypertension (adjusted odds ratio [aOR], 4.048; 95% confidence interval [CI], 1.14–14.32; p = 0.030), and male sex (aOR, 4.233; 95% CI, 1.09–16.48; p = 0.037) were independently associated with CMBs. Conclusion In young patients who presented with spontaneous ICH, CMBs were highly prevalent in 61% of patients and strongly associated with history of hypertension and male sex.
Collapse
Affiliation(s)
- Young-Min Lee
- Department of Neurosurgery and Neuroscience Radiosurgery Adaptive Hybrid Neurosurgery Research Center, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Hae-Won Koo
- Department of Neurosurgery and Neuroscience Radiosurgery Adaptive Hybrid Neurosurgery Research Center, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Hyung Koo Kang
- Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Jin Woo Kim
- Department of Radiology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Seong Rok Han
- Department of Neurosurgery and Neuroscience Radiosurgery Adaptive Hybrid Neurosurgery Research Center, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Sang Won Yoon
- Department of Neurosurgery and Neuroscience Radiosurgery Adaptive Hybrid Neurosurgery Research Center, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Chan Young Choi
- Department of Neurosurgery and Neuroscience Radiosurgery Adaptive Hybrid Neurosurgery Research Center, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Moon-Jun Sohn
- Department of Neurosurgery and Neuroscience Radiosurgery Adaptive Hybrid Neurosurgery Research Center, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| | - Chae Heuck Lee
- Department of Neurosurgery and Neuroscience Radiosurgery Adaptive Hybrid Neurosurgery Research Center, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
| |
Collapse
|
143
|
Abstract
PURPOSE OF REVIEW Cerebral amyloid angiopathy (CAA) is diagnosed primarily as a cause of lobar intracerebral hemorrhages (ICH) in elderly patients. With improving MRI techniques, however, the role of CAA in causing other symptoms has become clear. Recognizing the full clinical spectrum of CAA is important for diagnosis and treatment. In this review we summarize recent insights in clinical CAA features, MRI biomarkers, and management. RECENT FINDINGS The rate of ICH recurrence in CAA is among the highest of all stroke subtypes. Cortical superficial siderosis (cSS) and cortical subarachnoid hemorrhage (cSAH) are important imaging predictors for recurrent ICH. CAA also causes cognitive problems in multiple domains. In patients with nondemented CAA, the risk of developing dementia is high especially after ICH. CAA pathology probably starts years before the first clinical manifestations. The first signs in hereditary CAA are white matter lesions, cortical microinfarcts, and impaired occipital cerebral vasoreactivity. Visible centrum semiovale perivascular spaces, lobar located lacunes, and cortical atrophy are new nonhemorrhagic MRI markers. SUMMARY CAA should be in the differential diagnosis of elderly patients with lobar ICH but also in those with cognitive decline and episodic transient neurological symptoms. Physicians should be aware of the cognitive effects of CAA. In patients with a previous ICH, cSS, or cSAH, anticoagulation should be considered risky. The increasing number of MRI markers may help to discriminate CAA from other small vessel diseases and dementia subtypes.
Collapse
|
144
|
Schreiber S, Scheumann V, Perosa V, Vielhaber S, Assmann A. Reader response: Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology 2018; 90:1126. [PMID: 29891580 DOI: 10.1212/wnl.0000000000005672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
145
|
Tsai HH, Kim JS, Jouvent E, Gurol ME. Updates on Prevention of Hemorrhagic and Lacunar Strokes. J Stroke 2018; 20:167-179. [PMID: 29886717 PMCID: PMC6007298 DOI: 10.5853/jos.2018.00787] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 05/16/2018] [Accepted: 05/23/2018] [Indexed: 12/22/2022] Open
Abstract
Intracerebral hemorrhage (ICH) and lacunar infarction (LI) are the major acute clinical manifestations of cerebral small vessel diseases (cSVDs). Hypertensive small vessel disease, cerebral amyloid angiopathy, and hereditary causes, such as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), constitute the three common cSVD categories. Diagnosing the underlying vascular pathology in these patients is important because the risk and types of recurrent strokes show significant differences. Recent advances in our understanding of the cSVD-related radiological markers have improved our ability to stratify ICH risk in individual patients, which helps guide antithrombotic decisions. There are general good-practice measures for stroke prevention in patients with cSVD, such as optimal blood pressure and glycemic control, while individualized measures tailored for particular patients are often needed. Antithrombotic combinations and anticoagulants should be avoided in cSVD treatment, as they increase the risk of potentially fatal ICH without necessarily lowering LI risk in these patients. Even when indicated for a concurrent pathology, such as nonvalvular atrial fibrillation, nonpharmacological approaches should be considered in the presence of cSVD. More data are emerging regarding the presentation, clinical course, and diagnostic markers of hereditary cSVD, allowing accurate diagnosis, and therefore, guiding management of symptomatic patients. When suspicion for asymptomatic hereditary cSVD exists, the pros and cons of prescribing genetic testing should be discussed in detail in the absence of any curative treatment. Recent data regarding diagnosis, risk stratification, and specific preventive approaches for both sporadic and hereditary cSVDs are discussed in this review article.
Collapse
Affiliation(s)
- Hsin-Hsi Tsai
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.,Department of Neurology, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan
| | - Jong S Kim
- Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Eric Jouvent
- Department of Neurology, University Paris Diderot, Paris, France
| | - M Edip Gurol
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
146
|
Tsai YH, Lee M, Lin LC, Chang SW, Weng HH, Yang JT, Huang YC, Lee MH. Association of Chronic Kidney Disease With Small Vessel Disease in Patients With Hypertensive Intracerebral Hemorrhage. Front Neurol 2018; 9:284. [PMID: 29780349 PMCID: PMC5946026 DOI: 10.3389/fneur.2018.00284] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 04/11/2018] [Indexed: 01/22/2023] Open
Abstract
Background Chronic kidney disease (CKD) has been closely associated with hypertension and stroke. Although studies have reported the relationship between CKD and cerebral small vessel disease (SVD), the link between CKD, hypertension, and SVD is uncertain. The aim of this study was to investigate the association between CKD and SVD in patients with strictly hypertensive intracerebral hemorrhage (ICH). Methods 142 patients with acute hypertensive ICH were enrolled in this study. Magnetic resonance imaging was performed to assess imaging markers for SVD. Patients were categorized into three CKD groups based on the degree of kidney dysfunction [glomerular filtration rate (GFR) in milliliters per minute per 1.73 m2]: normal kidney function (GFR ≥ 90), mild kidney disease (60 ≤ GFR < 90), and moderate to severe kidney disease (GFR < 60). Results The prevalence rate of mild and moderate to severe CKD was 50 and 14.8%, respectively. The stage of CKD was associated with history of chronic hypertension (p = 0.046) as well as the prevalence rate of overall and deep cerebral microbleed (CMB) (p = 0.001 and p = 0.002, respectively). The stage of CKD was a significant risk factor for deep white matter hyperintensity (WMH) (OR 1.848; 95% CI 1.022–3.343, p = 0.042), overall CMB (OR 2.628; 95% CI 1.462–4.724, p = 0.001), lobar CMB (OR 2.106; 95% CI 1.119–3.963, p = 0.021), and deep CMB (OR 2.237; 95% CI 1.263–3.960, p = 0.006), even after adjustment for confounders. Conclusion In patients with hypertensive ICH, the prevalence of CKD is high even at the early stage of renal function impairment and is associated with the prevalence of CMB and deep WMH. These results reinforce the notion of a link between hypertensive vasculopathy, renal function impairment, and cerebral SVD.
Collapse
Affiliation(s)
- Yuan-Hsiung Tsai
- Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.,College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Meng Lee
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.,Department of Neurology, Chang Gung Memorial Hospital, Chiayi, Taiwan
| | - Leng-Chieh Lin
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.,Department of Emergency Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan
| | - Sheng-Wei Chang
- Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.,College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Hsu-Huei Weng
- Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.,College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Jen-Tsung Yang
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.,Department of Neurosurgery, Chang Gung Memorial Hospital, Chiayi, Taiwan
| | - Yen-Chu Huang
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.,Department of Neurology, Chang Gung Memorial Hospital, Chiayi, Taiwan
| | - Ming-Hsueh Lee
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.,Department of Neurosurgery, Chang Gung Memorial Hospital, Chiayi, Taiwan
| |
Collapse
|
147
|
Primary Intracerebral Hemorrhage: A Closer Look at Hypertension and Cerebral Amyloid Angiopathy. Neurocrit Care 2018; 29:77-83. [DOI: 10.1007/s12028-018-0514-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
148
|
Lang B, Kindy MS, Kozel FA, Schultz SK, Taheri S. Multi-Parametric Classification of Vascular Cognitive Impairment and Dementia: The Impact of Diverse Cerebrovascular Injury Biomarkers. J Alzheimers Dis 2018; 62:39-60. [DOI: 10.3233/jad-170733] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Brittany Lang
- Clinical Psychology Program, University of South Florida, Tampa, FL, USA
| | - Mark S. Kindy
- Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida Tampa, FL, USA
- James A. Haley VA Medical Center, Tampa, FL, USA
| | - F. Andrew Kozel
- James A. Haley VA Medical Center, Tampa, FL, USA
- Psychiatry and Behavioral Sciences, University of South Florida, Tampa, FL, USA
| | - Susan K. Schultz
- James A. Haley VA Medical Center, Tampa, FL, USA
- Psychiatry and Behavioral Sciences, University of South Florida, Tampa, FL, USA
| | - Saeid Taheri
- Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida Tampa, FL, USA
- Byrd Alzheimer’s Institute, Tampa, FL, USA
| |
Collapse
|
149
|
Fotakopoulos G, Makris D, Tsianaka E, Kotlia P, Karakitsios P, Gatos C, Tzannis A, Fountas K. The value of the identification of predisposing factors for post-traumatic amnesia in management of mild traumatic brain injury. Brain Inj 2018; 32:563-568. [PMID: 29400569 DOI: 10.1080/02699052.2018.1432075] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECT To identify the risk factors for post-traumatic amnesia (PTA) and to document the incidence of PTA after mild traumatic brain injuries. METHODS This was a prospective study, affecting mild TBI (mTBI) (Glasgow Coma Scale 14-15) cases attending to the Emergency Department between January 2009 and April 2012 (40 months duration). Patients were divided into two groups (Group A: without PTA, and Group B: with PTA, and they were assessed according to the risk factors. RESULTS A total of 1762 patients (males: 1002, 56.8%) were meeting study inclusion criteria [Group A: n = 1678 (83.8%), Group B: n = 84 (4.2%)]. Age, CT findings: (traumatic focal HCs in the frontal and temporal lobes or more diffuse punctate HCs, and skull base fractures), anticoagulation therapy and seizures were independent factors of PTA. There was no statistically significant correlation between PTA and sex, convexity fractures, stroke event, mechanism of mTBI (fall +/or beating), hypertension, coronary heart disease, chronic smokers and diabetes (p > 0.005). CONCLUSION CT findings: (traumatic focal HCs in the frontal and temporal lobes or more diffuse punctate HCs and skull base fractures), age, seizures and anticoagulation/antiplatelet therapy, were independent factors of PTA and could be used as predictive factors after mTBI.
Collapse
Affiliation(s)
- George Fotakopoulos
- a Department of Neurosurgery , University Hospital of Thessaly, University Hospital of Larissa , Thessaly , Greece
| | - Demosthenes Makris
- b Department of Head of Critical Care , University Hospital of Larissa , Larissa , Greece
| | - Eleni Tsianaka
- a Department of Neurosurgery , University Hospital of Thessaly, University Hospital of Larissa , Thessaly , Greece
| | - Polikceni Kotlia
- b Department of Head of Critical Care , University Hospital of Larissa , Larissa , Greece
| | - Paulos Karakitsios
- c Department of General Medicine , Public Health System of Palamas , Palamas , Greece
| | - Charalabos Gatos
- a Department of Neurosurgery , University Hospital of Thessaly, University Hospital of Larissa , Thessaly , Greece
| | - Alkiviadis Tzannis
- a Department of Neurosurgery , University Hospital of Thessaly, University Hospital of Larissa , Thessaly , Greece
| | - Kostas Fountas
- a Department of Neurosurgery , University Hospital of Thessaly, University Hospital of Larissa , Thessaly , Greece
| |
Collapse
|
150
|
Greenberg SM, Charidimou A. Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria. Stroke 2018; 49:491-497. [PMID: 29335334 PMCID: PMC5892842 DOI: 10.1161/strokeaha.117.016990] [Citation(s) in RCA: 292] [Impact Index Per Article: 41.7] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 11/30/2017] [Accepted: 12/07/2017] [Indexed: 12/14/2022]
Affiliation(s)
- Steven M Greenberg
- From the Department of Neurology, Massachusetts General Hospital Stroke Research Center, Boston.
| | - Andreas Charidimou
- From the Department of Neurology, Massachusetts General Hospital Stroke Research Center, Boston
| |
Collapse
|